<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease - Gjuladin‐Hellon, T - 2019 | Cochrane Library</title> <meta content="Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease - Gjuladin‐Hellon, T - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010233.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease - Gjuladin‐Hellon, T - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010233.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010233.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease" name="citation_title"/> <meta content="Teuta Gjuladin‐Hellon" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Zipporah Iheozor‐Ejiofor" name="citation_author"/> <meta content="University of Central Lancashire" name="citation_author_institution"/> <meta content="Morris Gordon" name="citation_author"/> <meta content="Anthony K Akobeng" name="citation_author"/> <meta content="Sidra Medicine" name="citation_author_institution"/> <meta content="aakobeng@sidra.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD010233.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/08/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010233.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010233.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010233.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Azathioprine [*therapeutic use]; Crohn Disease [*drug therapy, prevention &amp; control, surgery]; Immunosuppressive Agents [*therapeutic use]; Maintenance Chemotherapy [*methods]; Mercaptopurine [*therapeutic use]; Randomized Controlled Trials as Topic; Remission Induction [methods]; Secondary Prevention" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010233.pub3&amp;doi=10.1002/14651858.CD010233.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010233\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010233\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fr","de","zh_HANT","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010233.pub3",title:"Azathioprine and 6\\u2010mercaptopurine for maintenance of surgically\\u2010induced remission in Crohn\u0027s disease",firstPublishedDate:"Aug 6, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010233.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010233.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010233.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010233.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010233.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010233.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010233.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010233.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010233.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010233.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2246 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010233.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-sec-0101"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/appendices#CD010233-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/table_n/CD010233StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/table_n/CD010233StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information#CD010233-cr-0002">Teuta Gjuladin‐Hellon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information#CD010233-cr-0003">Zipporah Iheozor‐Ejiofor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information#CD010233-cr-0004">Morris Gordon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information#CD010233-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Anthony K Akobeng</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information/en#CD010233-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 August 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010233.pub3">https://doi.org/10.1002/14651858.CD010233.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010233-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010233-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010233-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010233-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010233-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010233-abs-0001" lang="en"> <section id="CD010233-sec-0001"> <h3 class="title" id="CD010233-sec-0001">Background</h3> <p>Crohn's disease (CD) is a chronic relapsing inflammatory condition and maintenance of remission is a major issue as many patients fail to achieve remission with medical management and require surgical interventions. Purine analogues such as azathioprine (AZA) and 6‐mercaptopurine (6‐MP) have been used to maintain surgically‐induced remission in CD, but the effectiveness, tolerability and safety of these agents remains controversial. </p> </section> <section id="CD010233-sec-0002"> <h3 class="title" id="CD010233-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of purine analogues (AZA and 6‐MP) for maintenance of surgically‐induced remission in CD. </p> </section> <section id="CD010233-sec-0003"> <h3 class="title" id="CD010233-sec-0003">Search methods</h3> <p>We searched PubMed, MEDLINE, Embase, CENTRAL, and the Cochrane IBD Group Specialized Register from inception to 26 July 2018 (and from inception to 31 July 2019). In addition, we searched reference lists of all included studies and relevant reviews, conference proceedings and trials registers. </p> </section> <section id="CD010233-sec-0004"> <h3 class="title" id="CD010233-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) with a duration of at least three months that enrolled adults and children with surgically‐induced remission of CD and compared AZA or 6‐MP to no treatment, placebo or any other active intervention were considered for inclusion. </p> </section> <section id="CD010233-sec-0005"> <h3 class="title" id="CD010233-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trial eligibility, extracted data, assessed the risk of bias and assessed the certainty of the evidence using GRADE. The primary outcome was clinical relapse. Secondary outcomes included endoscopic relapse, radiologic and surgical relapse, adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs and health‐related quality of life. </p> </section> <section id="CD010233-sec-0006"> <h3 class="title" id="CD010233-sec-0006">Main results</h3> <p>Ten RCTs with a total of 928 participants were included. Study participants were adults recruited from university clinics and gastroenterology hospitals who received interventions post‐surgery for a duration between 12 to 36 months. Most study participants were recruited less than three months after surgery in all except one study where participants were recruited between 6 to 24 months post‐surgery. One study was rated as low risk of bias, six studies were rated high risk of bias and three were rated unclear risk of bias. </p> <p>There was moderate certainty evidence that purine analogues are more efficient for preventing clinical relapse than placebo. At 12 to 36 months, 51% (109/215) of AZA/6‐MP participants relapsed compared to 64% (124/193) of placebo participants (RR 0.79; 95% CI 0.67 to 0.92; 408 participants; 3 studies; I² = 0%; moderate certainty evidence). The certainty of the evidence regarding the efficacy of AZA or 6‐MP for maintaining postoperative clinical remission compared to 5‐ASA compounds was low. At 12 to 24 months , 64% (113/177) of purine analogue participants relapsed compared to 59% (101/170) of 5‐ASA participants (RR 1.05; 95% CI 0.89 to 1.24; 347 participants; 4 studies; I² = 8%; low certainty evidence). The certainty of evidence that purine analogues are inferior for preventing postsurgical clinical relapse compared to tumour necrosis factor alpha agents (anti‐TNF‐α) was very low. At 12 to 24 months, 43% (29/67) of AZA participants relapsed compared to 14% (10/72) of anti‐TNF‐α participants (RR 2.89; 95% CI 1.50 to 5.57; 139 participants; 3 studies; I² = 0%; very low certainty evidence). </p> <p>The effect of purine analogues compounds on AEs compared to placebo or any active treatment was uncertain, as the quality of evidence ranged from very low to low. After 12 to 24 months, 14% (12/87) of purine analogue participants experienced an AE compared to 10% (8/81) of placebo participants (RR 1.36; 95% CI 0.57 to 3.27; 168 participants; 2 studies; I² = 0%; low certainty evidence). The effect of purine analogues on AEs compared to 5‐ASA agents was uncertain. After 12 to 24 months, 41% (73/176) of purine analogue participants had an AE compared to 47% (81/171) of 5‐ASA participants (RR 0.89; 95% CI 0.74 to 1.07; 346 participants; 4 studies; I² = 15%; low certainty evidence). The effect of purine analogues on AEs in comparison to anti TNF‐α agents was uncertain. At 12 to 24 months, 57% (32/56) of AZA participants had an AE compared to 51% (31/61) of anti‐TNF‐α participants (RR 1.13; 95% CI 0.83 to 1.53; 117 participants; 2 studies; I² = 0%; low certainty evidence). Purine analogue participants were more like than 5‐ASA participants to have a SAE (RR 3.39, 95% CI 1.26 to 9.13, 311 participants; 3 studies; I² = 9%; very low certainty evidence), or to withdraw due to an AE (RR 2.21, 95% CI 1.28 to 3.81; 425 participants; 5 studies; I² = 0%; low certainty evidence). Commonly reported AEs across all studies included leucopenia, arthralgia, abdominal pain or severe epigastric intolerance, elevated liver enzymes, nausea and vomiting, pancreatitis, anaemia, nasopharyngitis and flatulence. </p> </section> <section id="CD010233-sec-0007"> <h3 class="title" id="CD010233-sec-0007">Authors' conclusions</h3> <p>Moderate certainty evidence suggests that AZA and 6‐MP may be superior to placebo for maintenance of surgically‐induced remission in participants with CD. There was no clear difference in the number of clinical relapses when purine analogues were compared with 5‐ASA agents, however this is based on low certainty evidence. There was very low certainty evidence that AZA and 6‐MP are more likely to result in more serious adverse events (SAEs) and withdrawals due to an AE (low certainty) when compared to 5‐ASA agents. Very low certainty evidence suggests that purine analogues may be inferior to anti‐TNF‐α agents, however, no firm conclusions can be drawn. Further research investigating the efficacy and safety of AZA and 6‐MP in comparison to other active medications in surgically‐induced remission of CD is warranted. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010233-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010233-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010233-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010233-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010233-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010233-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010233-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010233-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010233-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010233-abs-0003" lang="en"> <h3>Azathioprine and 6‐mercaptopurine for the maintenance of surgically‐induced remission in Crohn’s disease </h3> <p><b>What was the aim of this review?</b> </p> <p>The aim of this review was to understand the benefits and harms of purine analogues (azathioprine (AZA) and 6‐mercaptopurine (6‐MP)) used for maintaining remission following surgery in people with Crohn's disease (CD). </p> <p><b>What is Crohn's disease?</b> </p> <p>Crohn's disease is a chronic disease of the gut. The disease is known to constantly change from periods when sufferers have symptoms (relapse) to periods when the symptoms disappear (remission) for a short time. Symptoms include abdominal pain, diarrhoea and weight loss. People with Crohn's disease may undergo surgery to remove diseased parts of their gut. However, their symptoms can return after a short time. Different drugs can be given to ensure that people with Crohn's disease are free from symptoms for as long as possible. However, there are concerns about possible side effects that may arise. Purine analogues (AZA and 6‐MP) are a group of immunosuppressive drugs which have been used for over five decades to manage Crohn's disease. We researched whether purine antimetabolites can maintain remission in people with Crohn's disease after the diseased portion of their gut has been removed. </p> <p><b>What are the main results of the review?</b> </p> <p>The review authors found 10 relevant studies with a total of 928 participants, conducted across several European countries, Israel and the US. The studies included people with Crohn's disease over 16 years of age who had undergone surgery and were free from symptoms. These studies compared purine analogues with placebo (e.g. a sugar pill), or oral 5‐aminosalicylic acid (5‐ASA) formulations or with anti‐tumour necrosis factor‐alpha (anti‐TNF‐α) drugs. 5‐ASA and anti‐TNF‐ɑ drugs are used reduce inflammation (pain and swelling) in the gut. </p> <p>One study was high quality, while six studies were of lower quality and three studies did not report enough information to make a judgement on quality. Purine analogues are probably better than placebo for maintaining surgically‐induced remission of Crohn's disease (moderate certainty evidence). The analysis of studies that compared purine antimetabolites to 5‐ASA medications found no difference in the number of people who remained in remission. However, more people who received purine analogues experienced serious side effects or discontinued treatment due to side effects than those who received 5‐ASA (very low and low certainty evidence). The analysis of studies that compared purine analogues to anti‐TNF‐α drugs showed that purine analogues were less effective for maintaining remission of Crohn's disease after surgery. However, the overall certainty of evidence was very low. Well designed studies are needed to better understand the benefits and harms of purine analogues compared with anti‐TNF‐ɑ agents and other active drugs used for Crohn's disease. Due to sparse data and inconsistent reporting across all studies, the effect of purine analogues on side effects compared with placebo, 5‐ASA or biologics was uncertain. Commonly reported side effects across the studies included leucopenia (a reduction in the number of white cells in the blood), pancreatitis (inflamed pancreas), arthralgia (joint pain), abdominal pain or severe epigastric intolerance, elevated liver enzymes, nausea and vomiting, anaemia (low number of red blood cells), nasopharyngitis (common cold) and flatulence (intestinal gas). </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to 31 July 2019.</p> <p><b>Conclusions</b> </p> <p>There is moderate certainty evidence that AZA and 6‐MP may be superior to placebo for maintenance of surgically‐induced remission in participants with Crohn's disease. There was no clear difference in the number of clinical relapses when purine analogues were compared with 5‐ASA agents, however this was based on low certainty evidence. There was very low certainty evidence that AZA and 6‐MP are more likely to result in more serious side effects and withdrawals due to side effects when compared to 5‐ASA agents. Very low certainty evidence suggests that purine analogues may be inferior to anti‐TNF‐α agents for preventing relapse, however, no firm conclusions can be drawn. Further research investigating the benefits and harms of AZA and 6‐MP in comparison to other active medications in surgically‐induced remission of CD is warranted. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010233-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010233-sec-0107"></div> <h3 class="title" id="CD010233-sec-0108">Implications for practice</h3> <section id="CD010233-sec-0108"> <p>Moderate certainty evidence suggests that purine analogues may be superior to placebo for maintenance of surgically‐induced remission in participants with Crohn's disease. There was no clear difference in the number of clinical relapses when purine analogues were compared with 5‐ASA agents, however this is based on low certainty evidence and no firm conclusions can be drawn. However, participants taking purine analogues were more likely than 5‐ASA participants to experience serious adverse events and discontinue therapy due to adverse events. Very low certainty evidence suggests that AZA and 6‐MP may be inferior to anti‐TNF‐α agents, however, no firm conclusions can be drawn. </p> </section> <h3 class="title" id="CD010233-sec-0109">Implications for research</h3> <section id="CD010233-sec-0109"> <p>Further research investigating the efficacy and safety of AZA and 6‐MP in comparison to other active medications in surgically‐induced remission of Crohn's disease is warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010233-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010233-sec-0022"></div> <div class="table" id="CD010233-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine (100‐150 mg/day) or 6‐mercaptopurine (1 mg/kg/day ‐ 50 mg/day)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/> (0.67 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>408<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse defined as: a CDAI&gt;250 (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>); a CDAI&gt;150 and 100 point increase from baseline (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>) or a grading score &gt; 2 (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1,000<br/> (430 to 591) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Endoscopic relapse</b> </p> <p>Follow‐up:12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.64 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>321<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic relapse defined as an endoscopic score i ≥2 (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>752 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>639 per 1,000<br/> (481 to 849) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Surgical relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/> (0.57 to 3.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>168<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported adverse events include hair loss, leukopenia, diarrhoea, abdominal pain, hepatotoxicity and arthralgia </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000<br/> (56 to 323) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up:12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.78<br/> (0.39 to 8.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>327<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported serious adverse events include arthralgia, pancreatitis, leucopenia and bowel obstruction </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1,000<br/> (5 to 108) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.63 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>408<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal included abnormal blood results leading to temporary discontinuation of treatment in 28% of the participants. However, specific details on reasons for discontinuation were not clearly stated </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1,000<br/> (160 to 328) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due serious imprecision (233 events). </p> <p><sup>2</sup> Downgraded one level due to serious inconsistency ( I² = 64%). </p> <p><sup>3</sup> Downgraded one level due to serious imprecision (227 events). </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (20 events) and 95% CI which includes appreciable benefit and harm </p> <p><sup>5</sup> Downgraded two levels due to very serious imprecision (7 events) and 95% CI which includes appreciable benefit and harm </p> <p><sup>6</sup> Downgraded one level due to serious imprecision (100 events) and 95% CI which includes appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010233-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine compared to 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine (2 mg/kg/day) or 6‐mercaptopurine (50 mg/day)<br/> <b>Comparison:</b> 5‐aminosalicylic acid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐aminosalicylic acid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05 (0.89, 1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse defined as a clinical grading score ≥ 2 (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>;<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> <p>or CDAI ≥ 200 (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>556 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1,000<br/> (456 to 773) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Endoscopic relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/> (0.52 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic relapse defined as a Rugeerts score ≥ 2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>650 per 1,000<br/> (433 to 975) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.66 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Radiologic relapse defined as a radiographic grading score ≥ 2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>767 per 1,000<br/> (550 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Surgical relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.50 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Surgical relapse defined as a need for another surgery (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>366 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>297 per 1,000<br/> (183 to 472) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.74 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>346<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported adverse events include leukopenia, abdominal pain, nausea, nasopharyngitis, diarrhoea. and headache </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1,000<br/> (353 to 510) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.39<br/> (1.26 to 9.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>311<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported serious adverse events include postoperative bowel obstruction</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000<br/> (50 to 360) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.21 (1.28, 3.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>425<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal include Severe epigastric intolerance, increase in liver function test results, leukopenia, acute pancreatitis </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1,000<br/> (93 to 317) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (214 events) and 95% CI which includes no effect and appreciable harm </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision (26 events) and 95% CI which includes no effect and appreciable benefit </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (28 events) and 95% CI which includes no effect and appreciable benefit </p> <p><sup>5</sup> Downgraded two levels due to very serious imprecision (47 events) and 95% CI which includes appreciable benefit and harm </p> <p><sup>6</sup> Downgraded one level due to serious imprecision (154 events) and 95% CI which includes no effect and appreciable benefit </p> <p><sup>7</sup> Downgraded two levels due to serious imprecision (33 events) </p> <p><sup>8</sup> Downgraded one level due to serious imprecision (58 events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010233-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to anti TNF‐α for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine compared to anti‐TNF‐α for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine (2‐2.5 mg/kg/day) or 6‐mercaptopurine (1.5 mg/kg/day)<br/> <b>Comparison:</b>Anti‐TNF‐α </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐ TNF‐α</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.89<br/> (1.50 to 5.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>139<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse defined as: an HBI ≥2 (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>), a clinical recurrence grading score ≥2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> <p>or a CDAI score &gt;200 (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1,000<br/> (208 to 774) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Endoscopic relapse</b> Follow‐up: 12 to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.67<br/> (1.05 to 12.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic relapse defined as a Rugeerts score ≥ 2 (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>973 per 1,000<br/> (278 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Radiologic relapse defined as a radiographic grading score ≥ 2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) or magnetic resonance enterography score ≥2 (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>) </p> <p>*due to considerable heterogeneity (I² = 85%), data pooling was not feasible. It is uncertain whether azathioprine leads to a difference in radiologic relapse when compared to infliximab as the certainty of the evidence is very low (RR1.36, 95% CI 0.94 to 1.98; RR 12.24, 95% CI 1.8 to 83.12) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Surgical relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.83 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events include bronchitis, nasopharyngitis, arthralgia, nausea, abscess were reported in <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>. Full details were not reported in <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>574 per 1,000<br/> (422 to 778) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/> (0.17 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events not reported</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000<br/> (34 to 308) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.97<br/> (0.92 to 17.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>139<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal included severe nausea, leukopenia, arthralgia, urothelial carcinoma, dyspepsia, dyspnoea, death, atopic dermatitis and abdominal pain with increase in pancreatic enzymes </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1,000<br/> (26 to 478) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of bias </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision (39 events) </p> <p><sup>3</sup> Downgraded one level due to serious imprecision (65 events) </p> <p><sup>4</sup> Downgraded one level due to substantial heterogeneity (I² = 64%) </p> <p><sup>5</sup> Downgraded one level due to serious imprecision (63 events) </p> <p><sup>6</sup> Downgraded two levels due to very serious imprecision (13 events) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010233-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010233-sec-0023"></div> <section id="CD010233-sec-0024"> <h3 class="title" id="CD010233-sec-0024">Description of the condition</h3> <p>Crohn’s disease is a chronic idiopathic inflammatory disorder of the gastrointestinal tract with an etiology that combines genetic predisposition, environmental factors and an inappropriate immune response to the gut microbiota which may involve the whole gastrointestinal tract (<a href="./references#CD010233-bbs2-0024" title="AbrahamC , ChoJHN . Inflammatory Bowel Disease. New England Journal of Medicine2009;361(21):2066‐78. ">Abraham 2009</a>). There is no cure for the disease, and management strategies are mainly focused on induction and maintenance of remission. Approximately 75% of patients with Crohn's disease will eventually undergo surgical resection (<a href="./references#CD010233-bbs2-0027" title="BernellO , LapidusA , HellersG . Risk factors for surgery and postoperative recurrence in Crohn’s disease. Annals of Surgery2000;231(1):38‐45. ">Bernell 2000</a>), and this can induce remission. However, endoscopic recurrence of disease has been reported to be as high as 73% at one year post surgery (<a href="./references#CD010233-bbs2-0048" title="RutgeertsP , GeboesK , VantrappenG , BeylsJ , KerremansR , HieleM . Predictability of the postoperative course of Crohn’s disease. Gastroenterology1990;99(4):956‐63. ">Rutgeerts 1990</a>), and clinical relapse rates have been reported to range from 22 to 55% at five years post surgery (<a href="./references#CD010233-bbs2-0056" title="WilliamsJG , WongWD , RothenbergerDA , GoldbergSM . Recurrence of Crohn's disease after resection. British Journal of Surgery1990;78(1):10‐9. ">Williams 1990</a>). There is no standard therapy for the prevention of postoperative recurrence in Crohn's disease (<a href="./references#CD010233-bbs2-0041" title="HanauerSB , SandbornW . Management of Crohn’s disease in adults. American Journal of Gastroenterology2001;96(3):635‐43. ">Hanauer 2001</a>). A number of agents have been studied, but considerable uncertainty remains as to the efficacy of such treatments. </p> </section> <section id="CD010233-sec-0025"> <h3 class="title" id="CD010233-sec-0025">Description of the intervention</h3> <p>Corticosteroids, the mainstay of treatment of acute exacerbations, have been used extensively as Crohn's disease therapy. However, the chronic use of glucocorticosteroids is limited due to the multiple adverse reactions and the lack of effectiveness for maintaining remission in Crohn's disease (<a href="./references#CD010233-bbs2-0052" title="SteinhartAH , EweK , GriffithsAM , ModiglianiR , ThomsenOO . Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD000301] ">Steinhart 2003</a>). 5‐aminosalicylic acid (5‐ASA) agents have been shown to be safe and may be effective for maintenance of post‐surgical remission, although the existing data suggests that the efficacy of these agents depends on the ability of these drugs to reach the terminal ileum and colon in therapeutic concentrations and may have limited clinical efficacy (<a href="./references#CD010233-bbs2-0038" title="GordonM , NaidooK , ThomasAG , AkobengAK . Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD008414.pub2] ">Gordon 2011</a>). Probiotics and budesonide do not appear to provide any benefit for maintenance of surgically‐induced remission in Crohn's disease (<a href="./references#CD010233-bbs2-0026" title="BenchimolEI , SeowCH , OtleyAR , SteinhartAH . Budesonide for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD002913.pub2] ">Benchimol 2009</a>; <a href="./references#CD010233-bbs2-0032" title="DohertyG , BennettG , PatilS , CheifetzA , MossAC . Interventions for prevention of post‐operative recurrence of Crohn's disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006873.pub2] ">Doherty 2009</a>; <a href="./references#CD010233-bbs2-0047" title="RolfeVE , FortunPJ , HawkeyCJ , Bath‐HextallFJ . Probiotics for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD004826.pub2] ">Rolfe 2006</a>). Nitroimidazole antibiotics may reduce the risk of relapse in surgically‐induced remission, however, these agents are not well tolerated and are associated with a higher risk of serious adverse events (<a href="./references#CD010233-bbs2-0032" title="DohertyG , BennettG , PatilS , CheifetzA , MossAC . Interventions for prevention of post‐operative recurrence of Crohn's disease. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006873.pub2] ">Doherty 2009</a>). Studies have demonstrated that tumour necrosis factor‐alpha (TNF‐α) antagonists such as infliximab (<a href="./references#CD010233-bbs2-0046" title="RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PasciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441–50. ">Regueiro 2009</a>), or adalimumab (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) may provide a benefit for reducing the risk of relapse in surgically‐induced remission, but these agents are expensive. Purine analogues such as azathioprine (AZA) and 6‐mercaptopurine (6‐MP) have been used in clinical practice for over five decades with a demonstrated efficacy for the long‐term maintenance of remission in both Crohn's disease (<a href="./references#CD010233-bbs2-0030" title="ChandeN , PattonPH , TsoulisDJ , ThomasBS , MacDonaldJK . Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD000067.pub3] ">Chande 2015</a>), and ulcerative colitis (<a href="./references#CD010233-bbs2-0054" title="TimmerA , PattonPH , ChandeN , McDonaldJW , MacDonaldJK . Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD000478.pub4] ">Timmer 2016</a>), and are relatively inexpensive. Evidence suggests that the effect of thiopurine formulations seem to last for up to five years (<a href="./references#CD010233-bbs2-0034" title="FraserAG , OrchardTR , JewellDP . The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut2002;50(4):485‐89. ">Fraser 2002</a>), significantly reducing the risk of perianal and intestinal surgery (<a href="./references#CD010233-bbs2-0029" title="CamusM , SeksikP , BourrierA , Nion‐LarmurierI , SokolH . Long‐term outcome of patients with Crohn’s disease who respond to azathioprine. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association2013;11(4):389‐394. ">Camus 2013</a>). </p> </section> <section id="CD010233-sec-0026"> <h3 class="title" id="CD010233-sec-0026">How the intervention might work</h3> <p>6‐MP and its prodrug AZA which is non‐enzymatically degraded to 6‐MP are purine antimetabolites that reduce cell proliferation and have immune modulating properties. 6‐MP is metabolised to its active component 6‐thioguanine nucleotide which competitively interferes with nucleic acid metabolism by inhibiting the proliferation of T and B lymphocytes and reducing the numbers of cytotoxic T cells and plasma cells (<a href="./references#CD010233-bbs2-0044" title="LennardL . The clinical pharmacology of 6‐mercaptopurine. European Journal of Clinical Pharmacology1992;43(4):329‐39. ">Lennard 1992</a>; <a href="./references#CD010233-bbs2-0049" title="SahasranamanS , HowardD , RoyS . Clinical pharmacology and pharmacogenetics of thiopurines. European Journal ofClinical Pharmacology2008;64:753‐67. ">Sahasranaman 2008</a>). There are some trial data which suggest that neutrophil count is a predictor of induction and maintenance of remission (<a href="./references#CD010233-bbs2-0031" title="ColonnaT , KorelitzBI . The role of leukopenia in the 6‐mercaptopurine induced remission of refractory Crohn's disease. American Journal of Gastroenterology1994;89(3):362‐6. ">Colonna 1994</a>), which may suggest the mechanism of action, although this is not well understood. The major limiting factor for long term use of AZA and 6‐MP agents has been the occurrence of adverse events in approximately 10% of patients leading to withdrawal of therapy (<a href="./references#CD010233-bbs2-0040" title="HafraouiS , DewitO , MarteauP , CosnesJ , ColombelJF , ModiglianiR , et al. Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate [Le mycophénolate mofétil dans les formes chroniques actives de la maladie de Crohn après échec de lazathioprine ou du méthotrexate]. Gastroenterologie Clinique et Biologique2002;26(1):17‐22. ">Hafraoui 2002</a>), with dose‐dependent and idiosyncratic adverse events occurring. There is evidence which suggests that thiopurine methyltransferase deficiency accounts for some of the dose and metabolism‐related toxicity to purine analogues including leucopenia, thrombocytopenia and in the long‐term potentially lymphoma and non‐melanoma skin cancer (<a href="./references#CD010233-bbs2-0025" title="AxelradJE , RoyA , LawlorG , KorelitzB , LichtigerS . Thiopurines and inflammatory bowel disease: current evidence and a historical perspective. World Journal of Gastroenterology2016;22:101‐3. ">Axelrad 2016</a>; <a href="./references#CD010233-bbs2-0037" title="GomollónF , DignassA , AnneseV , TilgH , VanAsscheG , LindsayJO , et al. 3rd European evidence‐based consensus on the management of Crohn’s disease 2016: Part 1: Diagnosis and medical management.. Journal of Crohn's &amp; Colitis2017;11:3‐25. ">Gomollon 2017</a>; <a href="./references#CD010233-bbs2-0043" title="LennardL , LoonJA , WeinshilboumRM . Pharmacogenitics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology and Therapeutics1989;46(2):149‐54. ">Lennard 1989</a>; <a href="./references#CD010233-bbs2-0055" title="WeinshilboumRN , SladekSL . Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics1980;32(5):651‐62. ">Weinshilboum 1980</a>), while adverse reactions such as arthralgias, pancreatitis, hepatitis, nausea, non‐pancreatic abdominal pain, rush, fever and diarrhoea are attributed to hypersensitivity reactions (<a href="./references#CD010233-bbs2-0050" title="SandbornWJ . A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6‐mercaptopurine, cyclosporine, and methotrexate. American Journal of Gastroenterology1996;91(3):423‐33. ">Sandborn 1996</a>). </p> </section> <section id="CD010233-sec-0027"> <h3 class="title" id="CD010233-sec-0027">Why it is important to do this review</h3> <p>Maintenance of remission in Crohn's disease is a major issue as many patients fail to achieve remission with medical management and require surgical interventions. Purine analogues have been used to maintain surgically‐induced remission in Crohn's disease, but the effectiveness, tolerability and safety of these drugs remains controversial. Relatively few studies have been published that investigate the role of AZA or 6‐MP for maintenance of remission following surgery in patients with Crohn's disease. One multicentre randomised placebo controlled trial involving 81 patients found a significant reduction in endoscopic recurrence when AZA was used in conjunction with metronidazole in comparison to metronidazole alone (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>). In another multicentre randomised controlled trial, it was concluded that 6‐mercaptopurine was more effective than either mesalamine or placebo at preventing postoperative recurrence at 24 months following surgery (<a href="./references#CD010233-bbs2-0041" title="HanauerSB , SandbornW . Management of Crohn’s disease in adults. American Journal of Gastroenterology2001;96(3):635‐43. ">Hanauer 2001</a>).  However, a single‐centre randomised open‐label trial found no significant difference in clinical relapse rates between AZA and mesalamine (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>). A previous review by this team in 2014 found evidence that purine analogues may be superior to placebo for maintenance of surgically‐induced remission in patients with Crohn's disease, although this was based on two small studies (<a href="./references#CD010233-bbs2-0057" title="GordonM , TaylorK , AkobengAK , ThomasAG . Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD010233.pub2] ">Gordon 2014</a>). The results for efficacy outcomes between purine analogues and 5‐ASA agents were uncertain. However, patients taking purine analogues were more likely than 5‐ASA patients to discontinue therapy due to adverse events. No firm conclusions could be drawn from the two small studies that compared AZA to infliximab or adalimumab. Adalimumab seemed superior to AZA but further research was needed to confirm these results. Hence, an up‐to‐date systematic review using the Cochrane Collaboration format was indicated to summarise the current evidence on the use of purine analogues for the maintenance of surgically‐induced remission in Crohn's disease. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010233-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010233-sec-0028"></div> <p>The primary objective was to evaluate the efficacy and safety of AZA and 6‐MP for maintenance of surgically‐induced remission in Crohn's disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010233-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010233-sec-0029"></div> <section id="CD010233-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010233-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials which compared AZA or 6‐MP agents to either a no treatment control, placebo or any other active intervention, with treatment durations of at least three months were considered for inclusion. </p> </section> <section id="CD010233-sec-0032"> <h4 class="title">Types of participants</h4> <p>Participants of any age and sex with a diagnosis of Crohn's disease confirmed by any established method who were in remission following surgery were considered for inclusion. Remission could be defined by a recognized Crohn's disease activity index such as the Crohn's disease activity index (CDAI) or endoscopy, or by participants who have undergone a curative surgical resection, or as defined by the authors of the primary studies. were considered for inclusion. Eligible trials could be conducted in any setting (e.g. single centre or multi‐centre). </p> </section> <section id="CD010233-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The controlled interventions of interest included any randomised controlled trial that compares oral AZA or 6‐MP agents to an no treatment, placebo or another active intervention for maintenance of surgically‐induced remission. Studies that compare AZA or 6‐MP agents to an intervention that focuses on enteral nutrition, oral nutrient supplementation, medical foods, probiotics, parental nutrition or herbal medicines were excluded. We also excluded dose optimisation studies. </p> </section> <section id="CD010233-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD010233-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measure was clinical relapse as defined by the primary studies.</p> </section> <section id="CD010233-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcome measures included the proportion of participants who experienced:</p> <p> <ul id="CD010233-list-0001"> <li> <p>Endoscopic relapse;</p> </li> <li> <p>Radiologic relapse;</p> </li> <li> <p>Surgical relapse;</p> </li> <li> <p>Histologic relapse;</p> </li> <li> <p>Adverse event (as defined by FDA 2018. We also noted where studies failed to provide sufficient information and simply report outcome as ‘adverse event’); </p> </li> <li> <p>Serious adverse events (as defined by FDA 2018. We also noted where studies failed to provide sufficient information and simply report outcome as ‘serious adverse event’); </p> </li> <li> <p>Withdrawal due to adverse events; and</p> </li> <li> <p>Health‐related quality of life (HRQoL).</p> </li> </ul> </p> <p>Adverse events and serious adverse events that are known to be associated with AZA or 6‐MP include: </p> <p> <ul id="CD010233-list-0002"> <li> <p>Bone marrow suppression: pancytopenia, leucopenia, neutropenia, thrombocytopenia;</p> </li> <li> <p>Hypersensitive reactions: malaise, vomiting, diarrhoea, rash, hypotension;</p> </li> <li> <p>Malignancy;</p> </li> <li> <p>Liver function impairment, jaundice;</p> </li> <li> <p>Pancreatitis;</p> </li> <li> <p>Pulmonary: pneumonitis; and</p> </li> <li> <p>Renal: interstitial nephritis.</p> </li> </ul> </p> <p>The outcome measures were reported at the last time point available (assumed to be at the end of follow‐up if not specified) and the time point specified in the methods as being of primary interest (if this was different from the latest time point available). However, it was also indicated when studies reported outcomes at other time points. </p> </section> </section> </section> <section id="CD010233-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010233-sec-0038"> <h4 class="title">Electronic searches</h4> <p>For the review update, we searched the following electronic databases from inception to 26 July 2018: </p> <p> <ul id="CD010233-list-0003"> <li> <p>MEDLINE;</p> </li> <li> <p>Embase;</p> </li> <li> <p>PubMed;</p> </li> <li> <p>CENTRAL; and</p> </li> <li> <p>Cochrane IBD Group Specialized Register.</p> </li> </ul> </p> <p>No restrictions were placed on language. Note that the searches were designed to include RCTs conducted on adults and children participants, but to exclude dose optimisation studies and trials that compare AZA or 6‐MP agents to oral nutrition supplements (enteral nutrition drinks, tube feeds), medical foods, probiotics, parenteral nutrition, herbal medicines or a combination of these modalities. The search strategy was more than one year old prior to publication of the updated review. Thus, we ran another search from inception to 31 July 2019 prior to publication. The search strategies are reported in <a href="./appendices#CD010233-sec-0113">Appendix 1</a>. </p> </section> <section id="CD010233-sec-0039"> <h4 class="title">Searching other resources</h4> <section id="CD010233-sec-0040"> <h5 class="title">Reference searching</h5> <p>We searched reference lists from included articles and any existing relevant reviews. We also searched ongoing trials registered on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform portal. </p> </section> <section id="CD010233-sec-0041"> <h5 class="title">Abstracts of major gastroenterology meetings</h5> <p>A manual search of abstracts and proceedings submitted to recent major gastroenterology meetings was performed for the following journals to identify more trials: </p> <p> <ul id="CD010233-list-0004"> <li> <p>Gastroenterology (American Gastroenterological Association);</p> </li> </ul> <ul id="CD010233-list-0005"> <li> <p>Gut (British Society of Gastroenterology);</p> </li> </ul> <ul id="CD010233-list-0006"> <li> <p>American Journal of Gastroenterology (American College of Gastroenterology); and</p> </li> </ul> <ul id="CD010233-list-0007"> <li> <p>Journal of Pediatric Gastroenterology and Nutrition (European / North American Society of Paediatric Gastroenterology, Hepatology and Nutrition). </p> </li> </ul> </p> <p>If a relevant abstract was identified, details of the full study methodology and results were requested from the authors in order to allow a thorough assessment of the quality of identified studies. </p> </section> </section> </section> <section id="CD010233-sec-0042"> <h3 class="title" id="CD010233-sec-0042">Data collection and analysis</h3> <p>This updated review was based upon the methods described in the published protocol (<a href="./references#CD010233-bbs2-0057" title="GordonM , TaylorK , AkobengAK , ThomasAG . Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD010233.pub2] ">Gordon 2014</a>), and in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD010233-bbs2-0042" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <section id="CD010233-sec-0043"> <h4 class="title">Selection of studies</h4> <p>The selection of studies included the following steps: title screening, abstract screening and full‐text review. Two authors (MG and TGH) independently reviewed each article at each stage of selection. Included and excluded studies were recorded. The two authors (MG and TGH) independently screened the titles using the titles of the papers that appeared to have even a minor possibility of inclusion. Adjudication did not occur at the title screening stage and studies that were ambiguous were included by default. The two authors (MG and TGH) then independently screened the abstracts of the articles that report studies with a reasonable possibility of inclusion. Differences in assessment for inclusion were resolved by discussion between the two independent investigators (MG and TGH). Adjudication did not occur at the abstract screening state. Lastly, the two authors (MG and TGH) independently screened the full text which involved selection of articles based on careful examination of the full report. Differences in assessment for inclusion were resolved by discussion between the two independent investigators. Adjudication was performed as needed by a third author (ZIE). </p> </section> <section id="CD010233-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>A data extraction form was developed to extract information on relevant features and results of included studies. Two authors (ZIE and TGH) independently extracted and recorded data on the predefined checklist. Extracted data included the following items: </p> <p> <ul id="CD010233-list-0008"> <li> <p>Study design: type of RCT, setting, number of interventions, year, author's contact;</p> </li> <li> <p>Population characteristics: age, sex, disease distribution, disease duration, site of disease, medication, type and time since operation, total number of participants originally assigned to each treatment group; </p> </li> <li> <p>Intervention: type and dose of agent;</p> </li> <li> <p>Control: no active treatment, placebo, other drugs;</p> </li> <li> <p>Concurrent medications; and</p> </li> <li> <p>Outcomes: time of assessment, length of follow up, type of Crohn's disease activity index used, definitions of remission and relapse, site of surgery, relapse rates, adverse events. </p> </li> </ul> </p> </section> <section id="CD010233-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (ZEI and TGH) independently assessed bias using the Cochrane risk of bias tool (<a href="./references#CD010233-bbs2-0042" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Adjudication was performed as needed by a third author (MG). Each domain was assessed as having a low, high, or unclear risk of bias. Domains assessed included: </p> <p> <ul id="CD010233-list-0009"> <li> <p>Sequence generation (i.e. was the allocation sequence adequately generated?);</p> </li> </ul> <ul id="CD010233-list-0010"> <li> <p>Allocation sequence concealment (i.e. was allocation adequately concealed?);</p> </li> </ul> <ul id="CD010233-list-0011"> <li> <p>Blinding (i.e. was knowledge of the allocated intervention adequately prevented during the study?); </p> </li> </ul> <ul id="CD010233-list-0012"> <li> <p>Incomplete outcome data (i.e. were incomplete outcome data adequately addressed?);</p> </li> </ul> <ul id="CD010233-list-0013"> <li> <p>Selective outcome reporting (i.e. are reports of the study free of suggestion of selective outcome reporting?); and </p> </li> </ul> <ul id="CD010233-list-0014"> <li> <p>Other potential sources of bias (i.e. was the study apparently free of other problems that could put it at a high risk of bias?). </p> </li> </ul> </p> <p>Each domain followed standard definitions used for Cochrane systematic reviews (<a href="./references#CD010233-bbs2-0042" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Study authors were contacted for further information when insufficient information was provided to determine the risk of bias. </p> <p>The overall certainty of the evidence was assessed using the GRADE approach (<a href="./references#CD010233-bbs2-0039" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. ">Guyatt 2008</a>; <a href="./references#CD010233-bbs2-0051" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Randomised trials start as high quality evidence, but may be downgraded due to: risk of bias (methodological quality), indirectness of evidence, unexplained heterogeneity, imprecision (sparse data) and publication bias. The overall quality of the evidence for each outcome was determined after considering each of these factors and graded as: </p> <p> <ul id="CD010233-list-0015"> <li> <p>High ‐ we are very confident that the true effect lies close to that of the estimate of the effect; </p> </li> <li> <p>Moderate ‐ we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; </p> </li> <li> <p>Low ‐ our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect; or </p> </li> <li> <p>Very low. We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> <section id="CD010233-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, risk ratio (RR) estimates and associated two‐sided 95% confidence intervals (CI) were calculated. For nominal or ordinal outcomes, we calculated the RR with corresponding 95% for each category relative to a reference category. For continuous outcomes, we calculated the mean difference (MD) and corresponding 95% CI. If studies in future updates report continuous outcomes that have been measured using different scales (e.g. IBDQ and SF‐36), we will calculate the standardised mean difference (SMD) and 95% CI. </p> </section> <section id="CD010233-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. We planned to include cross‐over trials if data were available from the first phase of the study (i.e. before cross‐over occurred). For outcomes where events recur (e.g. clinical relapses, adverse events), we calculated the proportion of participants who experienced at least one event, individual events were not counted separately. The studies were otherwise not anticipated to have repeated observations of outcomes or multiple treatment events. If studies had randomised subjects to more than one AZA or 6‐MP treatment arm, these groups would have been combined for the primary analysis. </p> </section> <section id="CD010233-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We collected information on how each trial handled missing data. When a study appeared to collect and not report all primary outcomes of interest, the original investigators were contacted to request missing data. If the original investigators did not provide the data, this would be noted in the systematic review. For studies with missing dichotomous data, an intention‐to‐treat analysis was performed where participants with missing data were assumed to have been treatment failures. </p> </section> <section id="CD010233-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity through visual inspection of the forest plots and by calculating the Chi² and I² statistics (<a href="./references#CD010233-bbs2-0028" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Introduction to meta‐analysis. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2009. ">Boreinstein 2009</a>). For studies that had qualitative homogeneity, statistical heterogeneity was assessed using the Chi² test (a P value &lt; 0.10 was considered statistically significant heterogeneity). The degree of heterogeneity across studies was estimated using the I² statistic. An I² of 25% or less was considered low heterogeneity, 26% to 50% was considered moderate heterogeneity, and 50% and greater was considered substantial heterogeneity. Where sufficient data are available, we planned to explore possible explanations for heterogeneity including factors such as participant characteristics (e.g. age, sex), condition severity, treatment type and dose, and healthcare system/country. Where appropriate, these factors were to be investigated further through sub‐group analyses and meta‐regression (<a href="./references#CD010233-bbs2-0028" title="BorensteinM , HedgesLV , HigginsJPT , RothsteinHR . Introduction to meta‐analysis. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2009. ">Boreinstein 2009</a>). Where sufficient data are available, we planned to use sensitivity analyses to explore possible causes of methodological heterogeneity (<a href="./references#CD010233-bbs2-0053" title="SuttonAJ , AbramsKR , JonesDR , SheldonTA , SongF . Methods for meta‐analysis in medical research. Chichester, West Sussex, UK: John Wiley &amp; Sons Ltd, 2000. ">Sutton 2000</a>). </p> </section> <section id="CD010233-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>If there were an appropriate number of studies in a pooled analysis (i.e. &gt; 10 studies), we planed to investigate potential publication bias using funnel plots (trial effects versus trial size) (<a href="./references#CD010233-bbs2-0033" title="EggerM , Davey‐SmithG , AltmanD (Editors) . Systematic reviews in health care: Meta‐analysis in context. Second Edition. London.: BMJ Publishing Group, 2001. ">Egger 2001</a>). However, the number of studies in each comparison group was smaller than 10. </p> </section> <section id="CD010233-sec-0051"> <h4 class="title">Data synthesis</h4> <p>Data from individual trials were combined for meta‐analysis if the interventions, patient groups and outcomes were sufficiently similar (determined by consensus). We calculated the pooled RR and corresponding 95% CI for dichotomous outcomes. Analyses were grouped by type of intervention treatment (e.g. AZA or 6‐MP versus placebo, AZA or 6‐MP versus 5‐ASA). Where there were multiple studies in an analysis we used a random‐effects model to obtain a more conservative interpretation otherwise, we used a fixed‐effect model. </p> </section> <section id="CD010233-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to assess the impact of potential effect modifiers such as age of participants (paediatric versus adult studies), drug type (azathioprine versus 6‐mercaptopurine) and length of follow‐up (12 months or less versus greater than 12 months). There were no studies on children. </p> </section> <section id="CD010233-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses based on random‐effects versus fixed‐effect models were planned where appropriate data or numbers of studies were available. Sensitivity analysis was also planned to explore possible explanations for significant heterogeneity. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010233-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010233-sec-0054"></div> <section id="CD010233-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD010233-sec-0056"> <h4 class="title">Results of the search</h4> <p>The original search for this update was conducted on 26 July 2018. The search expired before the update could be published, so we ran another search on 31 July 2019. The electronic database search conducted on 31 July 2019 identified 1201 records, while 37 records were found through other sources (See <a href="#CD010233-fig-0001">Figure 1</a>). Of the 52 full‐text records assessed for eligibility, 35 reports of 10 studies (928 participants) were included in this systematic review update. Two studies (<a href="./references#CD010233-bbs2-0022" title="NCT03185611 . Effectiveness of rifaximin combined with thiopurine on preventing postoperative recurrence in Crohn's disease. clinicaltrials.gov/ct2/show/NCT03185611 (accessed 14 June 2017). ">NCT03185611</a>; <a href="./references#CD010233-bbs2-0023" title="NL1344 . Azathioprine maintenance treatment versus infliximab maintenance treatment in Crohn’s disease patients in remission (Azorix trial). trialregister.nl/trial/1344 (accessed 1 August 2008). ">NL1344</a>), were classified as ongoing <a href="./references#CD010233-sec-0121" title="">Characteristics of ongoing studies</a>. Eleven studies (15 reports) were excluded for different reasons as presented in the <a href="./references#CD010233-sec-0120" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD010233-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010233-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Detailed information about all included studies are presented in the <a href="./references#CD010233-sec-0119" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD010233-sec-0057"> <h4 class="title">Included studies</h4> <section id="CD010233-sec-0058"> <h5 class="title">Study design and setting</h5> <p>This systematic review includes reports of single centre and multicentre randomised controlled trials with a parallel design with a duration of 52 weeks (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>), to 36 months (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). These studies were all published between 2004 and 2017. There were four single‐centre studies conducted in two different countries: Italy (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), and Israel (<a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). The multicentre studies were conducted across Belqium (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>), Spain (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>, the UK (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>), or as a multinational collaboration of several countries across Europe and Israel (<a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>), and Europe and the USA (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>). Regarding the care setting, three studies were conducted either in gastroenterology hospitals and medical clinics/centres (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>), and secondary and tertiary hospitals (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>), or as a collaboration between university clinics and hospitals and medical centres in four studies (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). The country and care setting were not reported in <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>. </p> </section> <section id="CD010233-sec-0059"> <h5 class="title">Participants</h5> <p>The total number of participants included in nine studies was 928 and ranged from 22 participants (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>), to 240 (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a> did not clearly report the number of participants randomised. All participants were adults with Crohn's disease who had undergone a resective surgical procedure to remove macroscopic disease. The majority of these participants were recruited within three months of surgery or before hospital discharge, except the 78 participants in <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a> who were enrolled between 6 and 24 months postoperatively. Interventions were conducted on participants with quiescent Crohn's disease and the disease activity prior to enrolment was established by generally accepted endoscopic, histological and radiological criteria. However, it is important to note that <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a> included participants in subsequent postoperative clinical remission (CDAI &lt; 200), but with signs of moderate to severe endoscopic recurrence. For this reason we only collected data on adverse events from <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>. </p> <p>The age of participants was reported nine studies and ranged between an average of 32.7 years (<a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>), to 40 years (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>) in seven trials. Two trials reported age as median (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>). All studies appear to have been conducted on a male and female adult population. None of the studies included paediatric participants. <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a> did not report any information about the age of participants. </p> </section> <section id="CD010233-sec-0060"> <h5 class="title">Interventions</h5> <p>All included studies were parallel two arm trials except for two studies that had three intervention arms (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). The duration of the intervention ranged from 52 weeks (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>), to 24 months (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). </p> <p>The studies compared the efficacy of AZA or 6‐MP agents with placebo or another active treatment. <a href="#CD010233-tbl-0004">Table 1</a> reports a summary of all interventions which are also summarized below: </p> <div class="table" id="CD010233-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Key definitions and outcomes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time from surgery till recruitment</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Site of surgery % / exclusions</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical relapse definition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic / surgical/ radiologic/ histological relapse definition/</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>AZA &amp; 6‐MP versus Placebo </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA versus Placebo (12 months)</p> <p>both arms 750 mg/day metronidazole</p> <p>(3 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perforating disease 48</p> <p>*Macroscopic evidence for CD proximally or distally to the site of resection or the presence of frank pancolitis or an ileorectal anastomosis, patients with a stoma; operation for fibrostenosis only </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 250</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 50 mg/day versus Placebo</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before postoperative hospital discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical recurrence grading &gt; 2 (Hanauer)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiographic relapse: </b> Radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 1 mg/kg/day versus Placebo</p> <p>(3 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 39; Colonic 2; Ileocolonic 59</p> <p>* Need for further surgery, stricturoplasty alone, formation of a stoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 150 and a 100‐point increase from baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>HRQOL:</b> IBDQ scores </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>AZA &amp; 6‐MP vs 5‐ASA </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg versus Mesalamine 3 mg/kg (24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small bowel only 25.3; Colon 5.6; Small bowel and colon 9.8; upper gastrointestinal tract 16.2 </p> <p>*Surgical procedures other than conservative surgery or for perianal disease only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 200</p> <p><b>Surgical relapse: </b> need for another surgical procedure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 50 mg/day versus Mesalamine 3 g/day</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before postoperative hospital discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinical recurrence grading &gt; 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiographic relapse: </b> radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg/day versus Mesalamine 4 g/day</p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p>* Short bowel syndrome, an ileocolonic stoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>HRQOL: IBDQ </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg/day versus Mesalazine 3 g/day</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51.</p> <p>* Fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 on the clinical recurrence grading scale by Hanauer</p> <p>2. CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i≥2</p> <p><b>Radiologic relapse </b>: ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQl: </b> IBDQ&gt;170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>AZA &amp; 6‐MP vs anti‐TNF‐α </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2.5 mg versus Infliximab 5 mg/kg</p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>*Active perianal disease, presence of stoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HBI ≥ 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts' score ≥ i2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg/day versus Adalimumab</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51.</p> <p>* Fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 on the clinical recurrence grading scale by Hanauer</p> <p>2. CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiologic relapse </b>: ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQl: </b> IBDQ &gt; 170 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2.5 mg/kg/day versus Adalimumab</p> <p>(52 weeks)</p> <p>both arms 750mg/day metronidazole</p> <p>(3 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 58, ileocolonic 41</p> <p>* Postsurgical stoma, resection for short indolent stenosis, inaccessible anastomosis to endoscopy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 1.5 mg/kg/day versus Adalimumab</p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 45 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 1.5 mg/kg/day vs Placebo (12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scapa 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 45 days</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AZA: azathioprine; 6‐MP: 6‐mecarptopurine; mg: milligram; CD: Crohn's disease; CDAI: Crohn's disease activity index; NA: not applicable; kg: kilogram; g: gram; HRQOL: health related quality of life; IBDQ: inflammatory bowel disease questionnaire; TNF: tumour necrosis factor; HBI: Harvey Bradshaw index; 5‐ASA: 5‐aminosalicylic acid </p> </div> </div> <section id="CD010233-sec-0061"> <h6 class="title">AZA or 6‐MP versus placebo</h6> <p> <ul id="CD010233-list-0016"> <li> <p>AZA versus placebo (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>). </p> </li> </ul> </p> <p>Both intervention arms also received concomitant metronidazole (750 mg/day) therapy for the first three months of the study (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>). </p> <p> <ul id="CD010233-list-0017"> <li> <p>6‐Mercaptopurine versus placebo (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). </p> </li> </ul> </p> </section> <section id="CD010233-sec-0062"> <h6 class="title">AZA or 6‐MP versus oral 5‐ASA agents</h6> <p> <ul id="CD010233-list-0018"> <li> <p>AZA versus mesalamine (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). </p> </li> <li> <p>6‐MP versus mesalamine (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>). </p> </li> </ul> </p> </section> <section id="CD010233-sec-0063"> <h6 class="title">AZA or 6‐MP versus anti‐TNF‐α</h6> <p> <ul id="CD010233-list-0019"> <li> <p>AZA versus infliximab (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>). </p> </li> <li> <p>AZA versus adalimumab (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). </p> </li> </ul> </p> <p>In <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> both intervention arms also received concomitant metronidazole (750 mg/day) therapy for the first three months of the study. </p> <p> <ul id="CD010233-list-0020"> <li> <p>6‐Mercaptopurine versus adalimumab (<a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). </p> </li> </ul> </p> <p>No studies that compared AZA or 6‐MP agents to a no treatment control group were identified.</p> <p>The use of concurrent treatment was discussed in all but two studies (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). In one study all participants were receiving oral metronidazole (500 mg/day) for two weeks after surgery (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>), while in two studies both intervention arms were administered metronidazole (ornidazole) for the first three months after surgery (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>). In <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a> any concomitant therapy had to be well documented and there was no reported use of active concomitant treatments. Corticosteroids were allowed to be tapered by standardized stepwise dose reductions in three studies (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>). Symptomatic treatment with antacids, antidiarrhoeal or spasmolytic medication on demand was permitted in three studies but had to be scrupulously recorded (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>). <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a> permitted topical therapy for perianal disease and cholestyramine for the treatment of bile‐acid diarrhoea. Continous use of nonsteroidal anti‐inflammatory drugs was prohibited and only occasional use of paracetamol and tramadol was allowed in <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>. </p> </section> </section> <section id="CD010233-sec-0064"> <h5 class="title">Outcomes</h5> <p>Outcomes were reported at multiple time points in two studies (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>), and at a single time point in eight studies (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). Some studies had followed participants beyond the intervention period, however, outcome data from those time points were not reported in this review. </p> <p>Outcomes of interest reported across studies included:</p> <section id="CD010233-sec-0065"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD010233-list-0021"> <li> <p>Clinical relapse (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). </p> </li> </ul> </p> </section> <section id="CD010233-sec-0066"> <h6 class="title">Secondary outcome</h6> <p> <ul id="CD010233-list-0022"> <li> <p>Endoscopic relapse (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). </p> </li> <li> <p>Radiological relapse (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). </p> </li> <li> <p>Histologic relapse (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>). </p> </li> <li> <p>Surgical relapse (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>). </p> </li> <li> <p>Adverse events (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). </p> </li> <li> <p>Serious adverse events (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>). </p> </li> <li> <p>Withrawal due to adverse events (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). </p> </li> </ul> </p> <p>A summary of interventions and outcomes is presented in additional <a href="#CD010233-tbl-0005">Table 2</a>. </p> <div class="table" id="CD010233-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of interventions and outcomes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quailty</b> </p> <p><b>of Life</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse</b> </p> <p><b>Events/</b> </p> <p><b>Serious</b> </p> <p><b>adverse/ Withdrawal due to adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3g/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 32/71 vs 35/71 </p> <p><b>Surgical:</b> 26/71 vs 21/71 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b>18/71 vs 27/71 </p> <p><b>SAE</b>:6/71 vs 15/71 </p> <p><b>Withdrwal due to AE:</b> 6/71 vs 15/71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2.5 mg/kg/day)</p> <p>Infliximab</p> <p>(5 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> <p>(5 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 2/11 vs 1/11 </p> <p><b>Endoscopic:</b> 5/11 vs 1/11; </p> <p><b>Histologic:</b> 9/11 vs 2/11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to AE:</b> 0/11 vs 1/11 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole (750 mg/day) first 3 mo +</p> <p>Azathioprine (100‐150 mg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole (750mg/day) first 3 months +</p> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 11/40 vs 19/41 </p> <p><b>Endoscopic:</b> 22/40 vs 32/41 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 3/40 vs 4/41 </p> <p><b>Withdrawal due to AE:</b> 3/40 vs 4/41 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐Mercaptopurine (50 mg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical:</b> 32/47 vs 33/44 vs 35/40 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 9/47 vs 6/44 vs 4/40 </p> <p><b>SAE:</b> 2/47 vs 0/44 vs 2/40 </p> <p><b>Withdrawal due to AE:</b> 9/47 vs 6/44 vs 4/40 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2.5 mg/kg/d) + Metronidazole (750 mg/day) first 3 mo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab + Metronidazole (750 mg/day) first 3 mo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical:</b> 14/39 vs 7/45 </p> <p><b>Endoscopic:</b> 23/39 vs 19/45 </p> <p><b>Radiologic:</b> 26/39 vs 22/45 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n.s. changes between groups</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 20/45 vs 18/39 </p> <p><b>SAE:</b> 9/45 vs 4/39 </p> <p><b>Withdrawal due to AE:</b> 1/39 vs 9/45 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mercaptopurine (1 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 66/128 vs 70/112 </p> <p><b>Endoscopic:</b> 90/128 vs 83/112 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n.s differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAE:</b> 3/128 vs 2/112 </p> <p><b>Withdrawal due to AE:</b> 39/128 vs 41/112 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2.0‐2.5 mg/kg/d) + Placebo mesalazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine (4g/d) +</p> <p>Placebo azathioprine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not included</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean IBDQ change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 34/37 vs 32/41 </p> <p><b>SAE:</b> 0/37 vs 10/41 </p> <p><b>Withdrawal due to AE:</b> 1/37 vs 10/41 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab (160‐80 mg 0‐2 weeks and 40 mg/week thereafter)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical by Hanauer score:</b> 2/16 vs 12/17 vs 9/18 </p> <p><b>Clinical by CDAI:</b> 1/16 vs 12/17 vs 9/18 </p> <p><b>Endoscopic:</b> 1/16 vs 11/17 vs 15/18 </p> <p><b>Radiologic:</b> 1/16 vs 13/17 vs 15/18 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (IBDQ &gt;170):</p> <p>14/16 vs 2/17 vs 3/18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b>11/16 vs 14/17 vs 14/18 </p> <p><b>Withdrawal due to AE:</b>0/16 vs 1/17 vs 1/18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐mercaptopurine (1.5 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab (160‐80‐40 mg/2 week intervals)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic:</b> 4/8 vs 1/11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>mg: milligram; kg: kilogram; g: gram; CDAI: Crohn's disease activity index; NA: not applicable; AE: adverse events; SAE: serious adverse events; HRQOL: health related quality of life; IBDQ: inflammatory bowel disease questionnaire; ns: not significant </p> </div> </div> </section> </section> <section id="CD010233-sec-0067"> <h5 class="title">Funding and conflict of interest</h5> <p>Four studies were reportedly supported by pharmaceutical companies (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>), but only two declared conflict of interest (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>). The author of one study was contacted to clarify the role of the pharmaceutical company and he confirmed that the company had no role in the study design, data analysis or writing of the paper (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>), whereas the remaining authors did not respond. Two studies were not supported by any grant (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> reported no conflicts of interest. <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a> reported receiving educational grants, and consultancy and lecture fees from a pharmaceutical company. <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a> was funded by a governmental grant and adequately reported on conflicts of interest. Funding and conflict of interest was not reported in two studies (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>, <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>), but our attempt to clarify this by contacting the authors was unsuccessful. </p> </section> </section> <section id="CD010233-sec-0068"> <h4 class="title">Excluded studies</h4> <p>Eleven studies (15 reports) were excluded for different reasons. The reasons for exclusion for each study are presented in the <a href="./references#CD010233-sec-0120" title="">Characteristics of excluded studies</a> table and are summarised below: </p> <p> <ul id="CD010233-list-0023"> <li> <p>Three studies were not RCTs (<a href="./references#CD010233-bbs2-0015" title="NosP , HinojosaJ , AguileraV , MolesJR , PastorM , PonceJ , et al. Azathiprine and 5‐ASA in the prevention of postoperative recurrence in Crohn's disease. Gastroenterología y Hepatología2000;23(8):374‐8. ">Nos 2000</a>; <a href="./references#CD010233-bbs2-0016" title="ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ">Reinisch 2013</a>; <a href="./references#CD010233-bbs2-0017" title="RobbPM , SorrentinoD . Long‐term prevention of postoperative Crohn's disease recurrence with azathioprine: the wolf in the sheep clothing. International Journal of Colorectal Disease2015;30(2):283‐4. ">Robb 2015</a>); </p> </li> </ul> <ul id="CD010233-list-0024"> <li> <p>Six studies assessed the wrong intervention (<a href="./references#CD010233-bbs2-0011" title="FerranteM , PapamichaelK , DuricovaD , D'HaensG , VermeireS , ArchavlisE , et al. Systematic versus Endoscopy‐driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. Journal of Crohn's and Colitis2015;9(8):617‐24. FerranteM , PapamichaelK , DuricovaD , D'HaensG , VermeireS , ArchavlisE , et al. Systematic versus endoscopy‐driven treatment with azathioprine to prevent postoperative ileal Crohn's disease recurrence. Journal of Crohn's and Colitis2014;8:S205‐6. FerranteM , PapamichaelK , DuricovaD , D'HaensGR , VermeireS , ArchavlisEJ , et al. Systematic versus endoscopy‐driven treatment with azathioprine to prevent postoperative ileal crohn's disease recurrence: Interim results from a randomized, multicenter trial. Gastroenterology2014;146(5 Suppl 1):S592. ">Ferrante 2015</a>; <a href="./references#CD010233-bbs2-0012" title="ManosaM , CabreE , BernalI , EsteveM , Garcia‐ PlanellaE , Ricart GomezE . Azathioprine versus azathioprine plus metronidazole for the prevention of postoperative endoscopic recurrence of Crohn's disease: A randomized, placebo controlled trial. Journal of Crohn's and Colitis2012;6:S93. MañosaM , CabréE , BernalI , EsteveM , Garcia‐PlanellaE , RicartE , et al. Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double‐blind, placebo‐controlled trial. Inflammatory Bowel Diseases2013;19(9):1889‐95. ">Mañosa 2013</a>; <a href="./references#CD010233-bbs2-0013" title="NCT01876264 . Crohn's extent of resection trial. clinicaltrials.gov/ct2/show/NCT01876264 (accessed 12 June 2013). ">NCT01876264</a>; <a href="./references#CD010233-bbs2-0019" title="WrightEK , CruzP , KammMA , HamiltonAL , RitchieKJ , KrejanyS , et al. Intestinal resection in Crohn's disease is associated with significant and durable improvement in health related quality of life although to a lesser extent in women and smokers. Results from the POCER study. Gastroenterology2014;146(5 Suppl 1):S435. ">Wright 2014</a>; <a href="./references#CD010233-bbs2-0020" title="WrightEK , KammMA , CruzP , HamiltonAL , RitchieK , BellSJ , et al. Structured post‐operative treatment and monitoring to prevent Crohn's disease recurrence is cost effective. Results from the POCER study. Journal of gastroenterology and hepatology2015;30:145. ">Wright 2015</a>; <a href="./references#CD010233-bbs2-0021" title="NCT01015391 . Efficacy study of T2 versus AZA to maintain clinical and endoscopic remission in postoperative Crohn's disease. clinicaltrials.gov/ct2/show/NCT01015391 (accessed 18 November 2009). ZhuW , LiY , GongJ , ZuoL , ZhangW , CaoL , et al. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Digestive &amp; Liver Disease2015;47(1):14‐9. ">Zhu 2015</a>); </p> </li> </ul> <ul id="CD010233-list-0025"> <li> <p>One study was terminated due to slow recruitment (<a href="./references#CD010233-bbs2-0014" title="NCT02247258 . Azathioprine in the prevention of ileal Crohn's disease postoperative recurrence. clinicaltrials.gov/ct2/show /NCT02247258 (accessed 23 September 2014). ">NCT02247258</a>); and </p> </li> </ul> <ul id="CD010233-list-0026"> <li> <p>One study assessed the wrong population (<a href="./references#CD010233-bbs2-0018" title="VidigalFM , deSouzaGS , ChebliLA , daRocha RibeiroTC , FurtadoMC , CastroAC , et al. Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. Medical Science Monitor2014;20:2165‐70. ">Vidigal 2014</a>). </p> </li> </ul> </p> </section> </section> <section id="CD010233-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias was assessed as low in one study (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>), high in six studies (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>), and unclear in three (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>). Details of the risk of bias assessment are presented in the <a href="./references#CD010233-sec-0119" title="">Characteristics of included studies</a> tables, and in <a href="#CD010233-fig-0002">Figure 2</a> and <a href="#CD010233-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010233-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010233-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD010233-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010233-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD010233-sec-0070"> <h4 class="title">Allocation</h4> <p><b>Random sequence generation</b> </p> <p>In all of the included studies the allocation of participants to an active treatment or placebo was reported as random. Eight studies were judged as being at low risk of bias for random sequence generation as these studies employed computer‐generated randomisation (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). Two studies were judged 'unclear' due to insufficient information on the method of randomisation (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). </p> <p><b>Allocation concealment</b> </p> <p>In six studies the method of allocation concealment was considered adequate (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). Four studies were judged as unclear risk of bias for allocation concealment as the methods were not adequately described (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). </p> </section> <section id="CD010233-sec-0071"> <h4 class="title">Blinding</h4> <p><b>Blinding of participants and personnel</b> </p> <p>Four of the studies included had an open‐label study design and were judged as being at high risk of bias (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). All the remaining studies were described as double‐blind. The method of blinding was not adequately described in three studies (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>), thus these studies were marked as 'unclear'. Two of these studies failed to describe whether the placebo was sufficiently identical to the intervention to blind study participants (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>), and one study provided insufficient information to make a judgement (<a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). Due to an adequate description of blinding methods, three studies were assessed as having low risk of performance bias (<a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>). </p> <p><b>Blinding of outcome assessment</b> </p> <p>We assessed one study as having a high risk of detection bias (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>). Four studies were marked as 'unclear' for detection bias, having failed to adequately describe blinding of outcome assessors (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). The rest of the studies were judged as having a low risk of detection bias, for clearly describing the methods regarding blinding of outcome assessment (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). </p> </section> <section id="CD010233-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>All except two studies reported data fully and documented dropouts and reasons for withdrawals. Incomplete outcome data in these studies was due to study termination (<a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>), and failure to report the number of randomised and withdrawn participants and reasons for withdrawal (<a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). The authors of <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a> were contacted for clarification, however no additional information was provided, except that the study is under preparation for publication. An 'unclear' judgment for this domain was not made for any of the studies. </p> </section> <section id="CD010233-sec-0073"> <h4 class="title">Selective reporting</h4> <p>Trial registration was available for four studies (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). Seven studies were judged as being at low risk of bias for reporting all outcomes prespecified in the trial registration or in the methods section of the study manuscript (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). One study was judged to be 'unclear' (<a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>). Two studies were marked 'high' for reporting bias: <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a> failed to report outcomes prespecified in the trial registration and <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> did not adequately report on a prespecified outcome. </p> </section> <section id="CD010233-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>Eight studies were judged to be at low risk of bias for other apparent sources of potential bias. Two studies provided insufficient information to enable the reviewers make a judgement and were rated as 'unclear' (<a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>). </p> </section> </section> <section id="CD010233-sec-0075"> <h3 class="title" id="CD010233-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD010233-tbl-0001"><b>Summary of findings for the main comparison</b> Azathioprine or 6‐mercaptopurine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</a>; <a href="./full#CD010233-tbl-0002"><b>Summary of findings 2</b> Azathioprine or 6‐mercaptopurine compared to 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease</a>; <a href="./full#CD010233-tbl-0003"><b>Summary of findings 3</b> Azathioprine or 6‐mercaptopurine compared to anti TNF‐α for maintenance of surgically‐induced remission in Crohn's disease</a> </p> <section id="CD010233-sec-0076"> <h4 class="title">AZA or 6‐MP versus placebo</h4> <p>Three studies that compared AZA (100 to 150 mg/day) or 6‐MP in doses of 50 mg/day and 1 mg/kg/day to placebo were identified (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). In one of these studies all participants were also taking either metronidazole or ornidazole (750 mg/day) for the first three months of intervention (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>). </p> <section id="CD010233-sec-0077"> <h5 class="title">Primary outcome</h5> <section id="CD010233-sec-0078"> <h6 class="title">Clinical relapse</h6> <p>Three studies reported on clinical relapse, with definitions for clinical relapse varying across studies. <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a> defined clinical relapse as a CDAI &gt; 250. <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a> defined clinical relapse as a CDAI &gt; 150 and a 100 point increase in CDAI from baseline. <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> defined relapse as a clinical reoccurrence grading score &gt; 2. There was moderate certainty evidence that AZA or 6‐MP are more efficient in preventing clinical relapse than placebo (<a href="./references#CD010233-fig-0004" title="">Analysis 1.1</a>; <a href="./full#CD010233-tbl-0001">summary of findings Table for the main comparison</a>). After a follow‐up of 12 to 36 months, 51% (109/215) of participants in the AZA/6‐MP group relapsed compared to 64% (124/193) of the placebo group (RR 0.79; 95% CI 0.67 to 0.92; 408 participants; 3 studies; I² = 0%; GRADE moderate certainty evidence). The subgroup analysis found no evidence of a difference in clinical relapse between AZA and 6‐MP (P = 0.34). A subgroup analysis based on length of follow‐up found no evidence of a difference in clinical relapse when measured at 12 months or less or at over 12 months (P = 0.34). </p> </section> </section> <section id="CD010233-sec-0079"> <h5 class="title">Secondary outcomes</h5> <p>The effect on endoscopic relapse rate as well as the tolerability and safety of AZA/6‐MP agents compared to placebo was uncertain, due to very low to low certainty evidence (<a href="./full#CD010233-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD010233-sec-0080"> <h6 class="title">Endoscopic relapse</h6> <p>Endoscopic relapse (<a href="./references#CD010233-fig-0006" title="">Analysis 1.3</a>), defined as endoscopic score i ≥ 2, was reported in two studies (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). During a follow‐up period of 12 to 36 months, 67% (112/168) of AZA/6‐MP participants relapsed endoscopically, compared to 75% (115/153) of placebo participants (RR 0.85; 95% CI 0.64 to 1.13; 321 participants; 2 studies; I² = 62%; GRADE low certainty evidence). We found no evidence of a difference in endoscopic relapse rates between AZA and 6‐MP (P = 0.11). A subgroup analysis based on length of follow‐up found no evidence of a difference in endoscopic relapse rates measured at different times (P = 0.11). <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> compared endoscopic relapse rates (defined as i ≥ 2<i>)</i> between the 6‐MP (16%; 95% CI 7% to 35%) and placebo (42%; 95% CI 21% to 70%) groups at 24 months (HR 0.48; reported P = 0.13; 87 participants). However, these data were insufficiently reported to be included in the meta‐analysis. </p> <p><b>Radiologic relapse</b> </p> <p>Radiologic relapse rate defined as a radiographic recurrence grading score ≥ <i>2</i> was reported in <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>. After 24 months, 33% (95% CI, 19% to 54%) of participants treated with 6‐MP had radiologic relapse compared to 49% (95% CI, 30% to 72%) in the placebo group (HR, 0.61; reported P = 0.19; 84 participants). </p> </section> <section id="CD010233-sec-0081"> <h6 class="title">Adverse events, serious adverse events and withdrawal due to adverse events</h6> <p>There was no clear difference in the number of participants who experienced adverse events, serious adverse events or withdrawal due to adverse events when AZA/6‐MP drugs are compared to placebo. Adverse events (<a href="./references#CD010233-fig-0008" title="">Analysis 1.5</a>) were reported in two studies ( <a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>). For the follow‐up period of 12 to 24 months, 14% (12/87) of AZA/6‐MP participants experienced at least one adverse event that was possibly related to treatment compared to 10% (8/81) of the placebo participants (RR 1.36; 95% CI 0.57 to 3.27; 168 participants; 2 studies; I² = 0%; GRADE low certainty evidence). The subgroup analysis found no evidence of a difference in adverse events when AZA and 6‐MP were compared (P = 0.32). A subgroup analysis based on length of follow‐up found no evidence of a difference in adverse events when measured at 12 months or less and over 12 months (P = 0.32). Commonly reported adverse events included hair loss, leukopenia, diarrhoea, abdominal pain, hepatotoxicity and arthralgia. </p> <p>Two studies (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>), reported on serious adverse events (<a href="./references#CD010233-fig-0010" title="">Analysis 1.7</a>), and three studies reported on the number of withdrawn participants as a result of adverse reactions to the treatment (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). About 3% (5/175) of AZA/6‐MP participants and 1% (2/152) of placebo participants experienced serious adverse events during 12 to 36 months of intervention follow‐up (RR 1.78; 95% CI 0.39 to 8.18; 327 participants; 2 studies; I² = 0%; GRADE low certainty evidence). During the same period, almost an equal proportion of AZA/6‐MP (24%; 51/215) and placebo (25%; 49/193) participants were withdrawn from the study due to adverse events (RR 0.90; 95% CI 0.63 to 1.29; 408 participants; 3 studies; I² = 3%; GRADE moderate certainty evidence). A subgroup analysis found no evidence of a difference in withdrawal due to adverse events when AZA and 6‐MP were compared (P = 0.69). A subgroup analysis based on length of follow‐up found no evidence of a difference in withdrawals due to adverse events when measured at 12 months or less or at over 12 months (P = 0.69). Commonly reported serious adverse events included arthralgia, pancreatitis, leucopenia and bowel obstruction. Adverse events leading to withdrawal from the study included abnormal blood results leading to led to temporary discontinuation of treatment in 28% of the participants. However, specific details on reasons for discontinuation were not clearly reported. </p> </section> <section id="CD010233-sec-0082"> <h6 class="title">Health related quality of life</h6> <p>HRQoL was reported in one study with no difference in IBDQ scores between the two treatments group. However these data were insufficiently reported for inclusion in the analysis (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). </p> </section> </section> </section> <section id="CD010233-sec-0083"> <h4 class="title">AZA or 6‐MP versus 5‐ASA</h4> <p>A total of five studies compared the efficacy of AZA (2 to 2.5 mg/day) or 6‐MP (50 mg/day) to mesalamine (dose 3 to 4 g/day) (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). Due to the specific inclusion/exclusion criteria in <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a> (<a href="./references#CD010233-sec-0119" title="">Characteristics of included studies</a>), the clinical and endoscopic relapse data from this study were not included in meta‐analyses. </p> <section id="CD010233-sec-0084"> <h5 class="title">Primary outcome</h5> <section id="CD010233-sec-0085"> <h6 class="title">Clinical relapse</h6> <p>Clinical relapse defined as a clinical recurrence grading score ≥ 2 (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), or a CDAI ≥ 200 (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>), was reported in four studies. There was low certainty evidence on the efficacy of AZA or 6‐MP for maintaining postoperative clinical remission in comparison to 5‐ASA compounds (<a href="./references#CD010233-fig-0013" title="">Analysis 2.1</a>; <a href="./full#CD010233-tbl-0002">summary of findings Table 2</a>). At the end of the 24 month follow‐up, 64% (113/177) of AZA treated participants clinically relapsed compared to 59% (101/170) of 5‐ASA treated ones (RR 1.05, 95% CI 0.89 to 1.24, 347 participants, 4 studies, I² = 8%; GRADE low certainty evidence). We carried out a subgroup analysis and found no evidence of a difference in clinical relapse rates between AZA and 6‐MP (P = 0.18). A subgroup analysis based on length of follow‐up found no evidence of a difference in clinical relapse rates when measured at 12 months or less or at over 12 months (P = 0.97). </p> </section> </section> <section id="CD010233-sec-0086"> <h5 class="title">Secondary outcomes</h5> <section id="CD010233-sec-0087"> <h6 class="title">Endoscopic relapse</h6> <p>Endoscopic relapse was reported in one study (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), and was defined as a Rugeerts score ≥ 2. The efficacy of AZA in comparison to 5‐ASA formulations in preventing endoscopic relapse was uncertain, as the certainty of evidence was very low (<a href="./references#CD010233-fig-0015" title="">Analysis 2.3</a>; Summary of findings table 2). After 24 months, 65% (11/17) of AZA participants relapsed endoscopically compared to 83% (15/18) of 5‐ASA participants (RR 0.78; 95% CI 0.52 to 1.17; 35 participants; 1 study; GRADE very low certainty evidence). </p> </section> <section id="CD010233-sec-0088"> <h6 class="title">Radiologic relapse</h6> <p>Radiologic relapse (follow‐up 24 months), defined as radiographic recurrence grading score ≥ 2, was reported in one study (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) and meta‐analysis was not performed. There is a very low certainty evidence regarding the effect of purine analogues on radiologic relapse rate compared to 5‐ASA drugs (<a href="./references#CD010233-fig-0016" title="">Analysis 2.4</a>). Sixty‐four percent (13/17) of AZA participants experienced radiologic relapse compared to 83% (15/18) of 5‐ASA participants (RR 0.92; 95% CI 0.66 to 1.28; 35 participants; 1 study; GRADE very low certainty evidence). </p> <p>Endoscopic and radiologic relapse rates were reported by <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>, however the results were insufficient to be included in the meta‐analysis. At 24 months (participants 91), reported endoscopic and radiologic relapse rates were 16%; 95% CI 7% to 35% and 33%; 95% CI 19% to 54% in the purine antimetabolites compared to 48%; 95% CI 30% to 70% and 46%; 95% CI 29% to 66% in the mesalamine intervention respectively. </p> </section> <section id="CD010233-sec-0089"> <h6 class="title">Surgical relapse</h6> <p>Surgical relapse (follow‐up 24 months), defined as the need for another surgery was reported in <a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>. The effect of purine analogues compared to 5‐ASA for the maintenance of surgical remission was uncertain, because the quality of evidence was judged as very low (<a href="./references#CD010233-fig-0017" title="">Analysis 2.5</a>; <a href="./full#CD010233-tbl-0002">summary of findings Table 2</a>). During the follow‐up period of two years, the proportion of participants with surgical relapse was 37% (26/71) in the 5‐ASA group versus 30% (21/71) in the purine analogues group (RR 0.81; 95% CI 0.50 to 1.29; 142 participants; 1 study; GRADE very low certainty evidence). </p> </section> <section id="CD010233-sec-0090"> <h6 class="title">Adverse events, serious adverse events and withdrawal due to adverse events</h6> <p>Adverse events and withdrawal due to adverse events were reported in four studies (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), and five studies respectively (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0005" title="DilgerK , SchaeffelerE , LukasM , StrauchU , HerfarthH , MullerR , et al. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Therapeutic Drug Monitoring2007;29(1):1‐5. HerfarthH , ObermeierF , TjadenC , LukasM , SerclovaZ , DignassAU , et al. Double‐blind, double dummy, randomized, multicentre, comparative study on the efficacy and safety of azathioprine (AZA) versus mesalazine (5‐ASA) for prevention of postoperative endoscopic recurrence in Crohn’s disease. Gastroenterology2006;130(4 Suppl 2):A480‐1. HerfarthH , TjadenC , LukasM , ObermeierF , DilgerK , MullerR , et al. Adverse events in clinical trials with azathioprine and mesalamine for the prevention of postoperative recurrence of Crohn's disease. Gut2006;55(10):1526‐6. MullerR , HerfarthH . More information on 2006 study published in Gut. Email to Morris Gordon 2/5/2012. ">Herfarth 2006</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), while serious adverse events were reported in three studies (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>; <a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>; <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>). The effect of purine analogues when compared to 5‐ASA drugs on adverse events was uncertain, as the quality of evidence was low (<a href="./full#CD010233-tbl-0002">summary of findings Table 2</a>). During a follow‐up of 12 to 24 months, the proportion of participants who experienced at least one adverse event (<a href="./references#CD010233-fig-0018" title="">Analysis 2.6</a>) was 41% (73/176) and 48% (81/170) in the AZA/6‐MP and 5‐ASA groups respectively (RR 0.89; 95% CI 0.74 to 1.07; 346 participants; 4 studies; I² = 15%; GRADE low certainty evidence). We found no evidence of a difference in adverse events when we carried out a subgroup analysis comparing AZA to 6‐MP (P = 0.34). A subgroup analysis based on length of follow‐up found no evidence of a difference in adverse events when measured at 12 months or less or at over 12 months (P = 0.66). Commonly reported adverse events included leukopenia, abdominal pain, nausea, nasopharyngitis, diarrhoea. and headache. During a 12 to 24 months follow‐up, serious adverse events (<a href="./references#CD010233-fig-0020" title="">Analysis 2.8</a>) were experienced by 17% (27/159) of purine analogue participants compared to 4% (6/152) of 5‐ASA participants (RR 3.39; 95% CI 1.26 to 9.13; 311 participants; 3 studies; I² = 9%; GRADE very low certainty evidence). We found no evidence of a difference in serious adverse events when we carried out a subgroup comparing AZA to 6‐MP (P = 1.0). A subgroup analysis based on length of follow‐up found no evidence of a difference in serious adverse events when measured at 12 months or less or at over 12 months (P = 0.19). Commonly reported serious adverse events include postoperative bowel obstruction. The proportion of participants that withdrew from the trial due to an adverse event (<a href="./references#CD010233-fig-0022" title="">Analysis 2.10</a>) during 12 to 24 months follow‐up were 19% (42/218) versus 8% (16/207) in the AZA/6‐MP and 5‐ASA groups respectively (RR 2.21, 95% CI 1.28 to 3.81; participants = 425; studies = 5; I² = 0%; GRADE low certainty evidence). We found no evidence of a difference in withdrawals due to adverse event when AZA and 6‐MP were compared (P = 0.25). A subgroup analysis based on length of follow‐up found no evidence of a difference in withdrawal due to adverse events when measured at 12 months or less or at over 12 months (P = 0.46). Adverse events leading to withdrawal included severe epigastric intolerance, increase in liver function test results, leukopenia and acute pancreatitis. </p> </section> <section id="CD010233-sec-0091"> <h6 class="title">HRQoL</h6> <p>Two studies with a follow‐up of 12 to 24 months reported on HRQoL based on the IBDQ score (<a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). The effect of 5‐ASA agents on HRQoL was uncertain as a result of serious limitations due to unclear risk of performance and outcome assessment bias and high risk of performance bias and outcome assessment bias in each study respectively and very serious limitations due to sparse data in both studies. <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> reported on the proportion of participants with an IBDQ score &gt; 170 (ranging from 32 to 224), which is regarded as a symptomatic remission score (<a href="./references#CD010233-fig-0024" title="">Analysis 2.12</a>). After 24 months of follow‐up, 12% (2/17) of AZA treated participants reported an IBDQ score &gt;170 compared with 17% (3/18) of 5‐ASA participants (RR 0.71; 95% CI 0.13 to 3.72; 35 participants; 1 study; GRADE very low certainty evidence). <a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a>, assessed HRQoL based on the mean change of IBDQ scores compared to baseline (<a href="./references#CD010233-fig-0025" title="">Analysis 2.13</a>.) At 12 months, the mean IBDQ difference compared to baseline was 9 (SD 17.7) in the AZA group versus 5 (SD 27.4) in the 5‐ASA treated group (MD 4; CI 14.36 to ‐6.36; 78 participants; 1 study; GRADE very low certainty evidence). </p> </section> </section> </section> <section id="CD010233-sec-0092"> <h4 class="title">AZA or 6‐MP versus anti‐TNF‐α</h4> <p>Three studies comparing AZA to either infliximab (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>), or adalimumab (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), and one study comparing 6‐mercaptopurine to adalimumab (<a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>), were identified. For all of the studies, the intervention started within 45 days of surgery. In the <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> study all participants were also administered metronidazole (750 mg/day) for the first three months of the study. The total number of assessed participants was 157. </p> <section id="CD010233-sec-0093"> <h5 class="title">Primary outcome</h5> <section id="CD010233-sec-0094"> <h6 class="title">Clinical relapse</h6> <p>Clinical relapse (<a href="./references#CD010233-fig-0026" title="">Analysis 3.1</a>) was reported in three studies (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), and was defined as HBI ≥ 2 (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>), clinical recurrence grading score ≥2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) or CDAI score &gt;200 (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>). The certainty of evidence that AZA is inferior in preventing postsurgical clinical relapse compared to anti‐TNF‐α agents was very low (<a href="./full#CD010233-tbl-0003">summary of findings Table 3</a>). During a follow‐up of 12 to 24 months, 43% (29/67) of participants treated with AZA clinically relapsed compared to 14% (10/72) of participants in the anti‐TNF‐α group (RR 2.89, 95% CI 1.50 to 5.57, 139 participants, 3 studies, I² = 0%; GRADE very low certainty evidence). The subgroup analysis based on length of follow‐up found no evidence of a difference in clinical relapse when measured at 12 months or less or at over 12 months (P = 0.2). </p> </section> </section> <section id="CD010233-sec-0095"> <h5 class="title">Secondary outcomes</h5> <section id="CD010233-sec-0096"> <h6 class="title">Endoscopic relapse</h6> <p>Endoscopic relapse was reported in four studies and was defined as Rutgeerts score ≥2. The evidence that purine antimetabolites are less efficient than anti‐TNF‐α for maintaining endoscopic remission was very low (<a href="./references#CD010233-fig-0028" title="">Analysis 3.3</a>; <a href="./full#CD010233-tbl-0003">summary of findings Table 3</a>). The proportion of purine analogue participants with endoscopic relapse was 58% (43/74) compared to 26% (22/83) of anti‐TNF‐α participants (RR 3.67; 95% CI 1.05 to 12.81; 157 participants; 4 studies; I² = 64%; GRADE very low certainty evidence). We found no evidence of a difference in endoscopic relapse rates when we carried out a subgroup analysis to compare AZA to 6‐MP (P = 0.72). A subgroup analysis based on length of follow‐up found a quantitative difference in endoscopic relapse when measured at 12 months or less or at over 12 months (P = 0.2). </p> </section> <section id="CD010233-sec-0097"> <h6 class="title">Radiologic relapse</h6> <p>Radiologic relapse was reported in two studies, defined either as radiographic recurrence grading score ≥ 2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), or based on magnetic resonance enterography scores MR2 and MR3 (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>). The certainty of evidence that purine analogues are less efficient to prevent endoscopic relapse than adalimumab or infliximab was very low (<a href="./references#CD010233-fig-0030" title="">Analysis 3.5</a>; <a href="./full#CD010233-tbl-0003">summary of findings Table 3</a>). The proportion of participants with endoscopic relapse after 12 to 24 months follow‐up was 69% (39/56) and 38% (23/61) among the purine analogues and anti‐TNF‐α treated groups respectively. Data pooling for <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> (RR 1.36, 95% CI 0.94 to 1.98) and <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> (RR 12.24, 95% CI 1.8 to 83.12) was not feasible due to considerable heterogeneity (I² = 85%). The certainty of evidence was rated very low due to high risk of bias and very serious imprecision. </p> </section> <section id="CD010233-sec-0098"> <h6 class="title">Histologic relapse</h6> <p>Histologic relapse (<a href="./references#CD010233-fig-0031" title="">Analysis 3.6</a>), based on the scoring system modified by <a href="./references#CD010233-bbs2-0046" title="RegueiroM , SchrautW , BaidooL , KipKE , SepulvedaAR , PasciM , et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology2009;136(2):441–50. ">Regueiro 2009</a> was reported only in <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a> and a meta‐analysis was not performed. Histologic relapse during 12 months of follow‐up was detected in 82% (9/11) and 18% (2/11) participants of the AZA and infliximab groups respectively (RR 4.50; 95% CI 1.25 to 16.25). </p> </section> <section id="CD010233-sec-0099"> <h6 class="title">Adverse events, serious adverse events and withdrawal due to adverse events</h6> <p>Adverse events were reported in two studies (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). Withdrawals due to adverse events were reported in three studies ( <a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>), and serious adverse events were reported in one study (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>). The certainty of evidence regarding tolerability and safety of purine analogues in comparison to anti‐TNF‐α agents ranged from very low to low (<a href="./full#CD010233-tbl-0003">summary of findings Table 3</a>). There was no clear difference in the number of participants who experienced adverse events when AZA/6‐MP was compared to anti‐TNF‐α during the follow‐up of 12 to 24 months (<a href="./references#CD010233-fig-0032" title="">Analysis 3.7</a>). Fifty‐seven per cent (32/56) of AZA/6‐MP participants experienced at least one adverse event compared to 51% (31/61) of the anti‐TNF‐α group (RR 1.13; 95% CI 0.83 to 1.53; 117 participants; 2 studies; I² = 0%; GRADE low certainty evidence). A subgroup analysis based on length of follow‐up found no evidence of a difference in adverse events when measured at 12 months or less or at over 12 months (P = 0.65). Commonly reported adverse events included bronchitis, nasopharyngitis, arthralgia, nausea and abscess (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). Full details concerning adverse events were not reported in <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>. The evidence regarding serious adverse events comes from a single study and a meta‐analysis was not performed (<a href="./references#CD010233-fig-0034" title="">Analysis 3.9</a>). The proportion of participants with serious adverse events was 10% (4/39) and 20% (9/45) among the AZA and adalimumab groups respectively (RR 0.51; 95% CI 0.17 to 1.54; 84 participants; 1 study; GRADE very low certainty evidence). The types of serious adverse events were not described. Over a follow‐up that ranged from 12 to 24 months, 16% (11/67) of AZA/6‐MP treated participants were withdrawn from the study due to an adverse event compared to 3% (2/72) of the anti‐TNF‐α treated participants (RR 3.97; 95% CI 0.92 to 17.22; 139 participants; 3 studies; I² = 4%; GRADE low certainty evidence). A subgroup analysis based on length of follow‐up found no evidence of a difference in withdrawals due to adverse events when measured at 12 months or less or at over 12 months (P = 0.24). Adverse events leading to withdrawal included severe nausea, leukopenia, arthralgia, urothelial carcinoma, dyspepsia, dyspnoea, death, atopic dermatitis and abdominal pain with increase in pancreatic enzymes. </p> </section> <section id="CD010233-sec-0100"> <h6 class="title">Health related quality of life</h6> <p>A single study assessed health‐related quality of life (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>). At 24 months, an IBDQ &gt; 170 was recorded in 12% (2/17) of participants treated with AZA compared to 88% (14/16) treated with adalimumab (RR 0.13; 95% CI 0.04 to 0.50; 34 participants; 1 study). This outcome was also evaluated in <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> using the EuroQol‐5 dimensions questionnaire, however reported data were insufficient to be included in meta‐analysis. </p> <p><b>Special safety note</b> </p> <p>It is worth specifically noting that two adverse events leading to therapy cessation occurred in more than 1% of participants treated with purine analogues. Pancreatitis was a serious adverse event that led to withdrawal across several of the studies. However, the rate of occurrence was almost exclusively in participants receiving purine analogues (11 cases in 354 participants taking purine analogues, 3.1%) compared to no occurrences in any of the comparison groups (i.e. placebo, 5‐ASA or anti‐TNF‐α) in this review. Leucopenia occurred also almost exclusively in participants receiving purine analogues (9 cases in 354 participants, 2.5%) compared to no occurrences in all other groups. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010233-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010233-sec-0101"></div> <section id="CD010233-sec-0102"> <h3 class="title" id="CD010233-sec-0102">Summary of main results</h3> <p>Ten RCTs assessing the effectiveness of AZA and 6‐MP for maintaining surgically‐induced remission in Crohn's disease were studied. The studies recruited people with Crohn's disease over the age of 16 years who were in surgically‐induced remission. The participants were randomised after surgery to received AZA or 6‐MP, placebo, 5‐ASA agents or anti‐TNF‐α agents. </p> <p>We found moderate certainty evidence that AZA and 6‐MP are superior to placebo for preventing post‐surgical clinical relapse in Crohn's disease. There was low certainty evidence on the safety of AZA and 6‐MP when adverse events and serious adverse events were considered. The certainty of the evidence for withdrawal due to adverse events was moderate. This was due to imprecision resulting from very sparse data. </p> <p>There was no clear difference clinical relapse when AZA or 6‐MP was compared with 5‐ASA. There are considerable concerns raised with the safety profile of AZA and 6‐MP. For the safety outcome serious adverse events and withdrawals due to adverse events, 5‐ASA was found to be superior to AZA and 6‐MP. However, the certainty of evidence for the efficacy and safety outcomes were low due to high risk of performance bias and sparse data. </p> <p>There was very low certainty evidence that AZA and 6‐MP may be inferior to anti‐TNF‐α agents for preventing clinical relapse. We also found no clear difference in adverse events, serious adverse events or withdrawals due to adverse events when both outcomes were compared. This was also based on low certainty evidence. The evidence was downgraded due to high risk of performance bias and sparse data, therefore, the results should be interpreted with caution. </p> </section> <section id="CD010233-sec-0103"> <h3 class="title" id="CD010233-sec-0103">Overall completeness and applicability of evidence</h3> <p>We consider the evidence from this review to be applicable to most patients with post‐surgical remission of Crohn's disease. The evidence only assesses AZA or 6‐MP compared with placebo, 5‐ASA or anti‐TNF‐α agents. All outcomes which we had aimed to analyse were reported in the studies. However, other measures of relapse (endoscopic, histologic and surgical) and health related quality of life were sparsely reported. This meant that very little data were available for our analysis. The review found moderate certainty evidence on the efficacy of AZA and 6‐MP compared with placebo. This can be considered complete and not requiring new studies, however, the evidence comparing it with 5‐ASA and anti‐TNF‐α were of very low or low certainty. Therefore, additional studies may change the results. The use of concomitant treatments such as antidiarrhoeal agents, corticosteroids and antibiotics were reported in some studies. The circumstances in which these treatments were given were noted in the studies and judged to be reflective of clinical practice. </p> </section> <section id="CD010233-sec-0104"> <h3 class="title" id="CD010233-sec-0104">Quality of the evidence</h3> <p>The certainty of the evidence was rated very low to moderate. Overall, six studies were at high risk of bias and three were at unclear risk of bias. Downgrading for limitations was mostly due to lack of blinding and this was particularly common with the head to head comparisons of active drugs. For most of the outcomes, there was imprecision due to sparse data as the number of events ranged between seven and 154. For the clinical relapse outcome, the optimal information size was obtained from power calculations in the largest and most recent study (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>). Most of the results were consistent except in two instances where there was substantial statistical heterogeneity (I² between 62% and 64%). There was no indirectness as all the studies in the review met the criteria proposed in the scope of the review. We were unable to assess for publication bias due to insufficient data. </p> </section> <section id="CD010233-sec-0105"> <h3 class="title" id="CD010233-sec-0105">Potential biases in the review process</h3> <p>We attempted to reduce potential biases in the review process. A comprehensive literature search was performed to identify all eligible studies. Two review authors independently assessed studies for inclusion, extracted data and assessed study quality. </p> <p>All analyses were completed using the intention‐to‐treat principle, whereby participants with final missing outcomes were assumed to have relapsed. Given the high attrition rate in the purine analogue groups compared to the 5‐ASA groups, this may have affected the difference in clinical relapse rates between purine analogues and 5‐ASA. However, it is arguably a moot point given that even if purine analogues did have superior efficacy, it is difficult to rationalise the use on the basis of the poor adverse event profile in the published evidence. </p> <p>One of the included studies administered active concomitant treatments in both intervention arms. This was considered a source of clinical heterogeneity in analyses that included studies which had no concomitant treatments. We did not remove this study from the analyses as a sensitivity analysis showed no difference in the results. </p> </section> <section id="CD010233-sec-0106"> <h3 class="title" id="CD010233-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p>A recent Cochrane review assessing the use of AZA or 6‐MP for maintenance of medically‐induced remission in Crohn's disease revealed that the purine analogues are more effective than placebo, with higher response rates for AZA than 6‐MP (<a href="./references#CD010233-bbs2-0030" title="ChandeN , PattonPH , TsoulisDJ , ThomasBS , MacDonaldJK . Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD000067.pub3] ">Chande 2015</a>). These findings are mirrored in the four studies comparing purine analogues to placebo. No difference in efficacy was found between AZA or 6‐MP and 5‐ASA. This could be due to lower disease activity following resection of the gut than is achieved in medically‐induced remission of Crohn's disease, so that a milder anti‐inflammatory agent such as 5‐ASA, gives a better risk versus benefit ratio when compared to AZA and 6‐MP. It is also possible that the methodology of the included studies supports this hypothesis, with all but one study recruiting participants in the immediate post‐surgical setting. As such, the participants are potentially at their lowest period of disease activity clinically and microscopically. The findings regarding safety are also consistent with the two most common adverse events noted as pancreatitis and leucopenia. </p> <p>A Cochrane review looking at the use of 5‐ASA for the maintenance of surgically‐induced remission in Crohn's disease suggests that 5‐ASA may be superior to placebo (<a href="./references#CD010233-bbs2-0036" title="Gjuladin‐HellonT , GordonM , Iheozor‐EjioforZ , AkobengAK . Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2019, Issue 6. [DOI: 10.1002/14651858.CD008414.pub3] ">Gjuladin‐Hellon 2019</a>). It also suggested that 5‐ASA is a safe and well‐tolerated drug, as the incidence of adverse events was not different in participants receiving 5‐ASA compared to those receiving placebo. The results of this systematic review question the risk versus benefit balance of starting a purine analogue over 5‐ASA in postoperative Crohn's disease. </p> <p>The international guidance from the European Crohn's and colitis Organisation (ECCO) updated in 2016 is consistent with the findings of this review in that they do indicate a role for purine analogues (<a href="./references#CD010233-bbs2-0035" title="GionchettiP , DignassA , DaneseS , DiasFJM , RoglerG , LakatosPL , et al. on behalf of ECCO. 3rd European Evidenced‐based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2; Surgical Management and Special Situations. Journal of Crohn's and ColitisFebruary 2017;11(2):135‐49. ">Gionchetti 2016</a>), although they do not comment on the limitations of the evidence as identified in this review. Most importantly, the significant safety questions raised in the synthesis performed in this review are not discussed within the ECCO documents in this context (section 8G), although leucopenia is noted in medical induced remission maintenance (6E). The National Insitutue for Clinical and Care Excellence (NICE) in the UK suggests AZA as first line therapy in this context (<a href="./references#CD010233-bbs2-0045" title="National Institute of Health and Care Excellence. Crohn's Disease: management (CG152). Available: https://www.nice.org.uk/guidance/cg152/evidence/addendum‐pdf‐24895654212016. ">NICE 2016</a>), citing the previous version of this review in their 2016 guidance (<a href="./references#CD010233-bbs2-0057" title="GordonM , TaylorK , AkobengAK , ThomasAG . Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD010233.pub2] ">Gordon 2014</a>). Unlike ECCO, the NICE guidance makes no specific mention of safety concerns. Given one of the specific adverse events noted frequently (leucopenia) is recognised in the context of purine analogues, it is important to highlight that the risk of pancreatitis has not been highlighted in either guideline, despite being recognised as the most common serious adverse events in both Cochrane reviews on these medications. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010233-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010233-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010233-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010233-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 1 Clinical relapse at 12 to 36 months (subgroup by drug type)." data-id="CD010233-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 1 Clinical relapse at 12 to 36 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 2 Clinical relapse (subgroup by length of follow‐up)." data-id="CD010233-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 2 Clinical relapse (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 3 Endoscopic relapse at 12 to 36 months (subgroup by drug type)." data-id="CD010233-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 3 Endoscopic relapse at 12 to 36 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 4 Endoscopic relapse (subgroup by length of follow‐up)." data-id="CD010233-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 4 Endoscopic relapse (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 5 Adverse events at 12 to 24 months (subgroup by drug type)." data-id="CD010233-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 5 Adverse events at 12 to 24 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 6 Adverse events (subgroup by length of follow‐up)." data-id="CD010233-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 6 Adverse events (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 7 Serious adverse events at 24 to 36 months." data-id="CD010233-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 7 Serious adverse events at 24 to 36 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 8 Withdrawal due to adverse events at 12 to 36 months (subgroup by drug type)." data-id="CD010233-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 8 Withdrawal due to adverse events at 12 to 36 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 9 Withdrawal due to adverse events (subgroup by length of follow‐up)." data-id="CD010233-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Azathioprine or 6‐mercaptopurine versus placebo, Outcome 9 Withdrawal due to adverse events (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 1 Clinical relapse at 12 to 24 months (subgroup by drug type)." data-id="CD010233-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 1 Clinical relapse at 12 to 24 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 2 Clinical relapse (subgroup by length of follow‐up)." data-id="CD010233-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 2 Clinical relapse (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 3 Endoscopic relapse at 24 months." data-id="CD010233-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 3 Endoscopic relapse at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 4 Radiologic relapse at 24 months." data-id="CD010233-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 4 Radiologic relapse at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 5 Surgical relapse at 24 months." data-id="CD010233-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 5 Surgical relapse at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 6 Adverse events at 12 to 24 months (subgroup by drug type)." data-id="CD010233-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 6 Adverse events at 12 to 24 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 7 Adverse events (subgroup by length of follow‐up)." data-id="CD010233-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 7 Adverse events (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 8 Serious adverse events at 12 to 24 months (subgroup by drug type)." data-id="CD010233-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 8 Serious adverse events at 12 to 24 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 9 Serious adverse events (subgroup by length of follow‐up)." data-id="CD010233-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 9 Serious adverse events (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 10 Withdrawal due to adverse events at 12 to 24 months (subgroup by drug type)." data-id="CD010233-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 10 Withdrawal due to adverse events at 12 to 24 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 11 Withdrawal due to adverse events (subgroup by length of follow‐up)." data-id="CD010233-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 11 Withdrawal due to adverse events (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 12 HRQoL ‐ IBDQ &gt; 170 at 24 months." data-id="CD010233-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 12 HRQoL ‐ IBDQ &gt; 170 at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 13 HRQoL ‐ IBDQ at 12 months." data-id="CD010233-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid, Outcome 13 HRQoL ‐ IBDQ at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 1 Clinical relapse at 12 to 24 months." data-id="CD010233-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 1 Clinical relapse at 12 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 2 Clinical relapse (subgroup by length of follow‐up)." data-id="CD010233-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 2 Clinical relapse (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 3 Endoscopic relapse at 12 to 24 months (subgroup by drug type)." data-id="CD010233-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 3 Endoscopic relapse at 12 to 24 months (subgroup by drug type). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 4 Endoscopic relapse (subgroup by length of follow‐up)." data-id="CD010233-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 4 Endoscopic relapse (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 5 Radiologic relapse at 12 to 24 months." data-id="CD010233-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 5 Radiologic relapse at 12 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 6 Histologic relapse at 12 months." data-id="CD010233-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 6 Histologic relapse at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 7 Adverse events at 12 to 24 months." data-id="CD010233-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 7 Adverse events at 12 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 8 Adverse events (subgroup by length of follow‐up)." data-id="CD010233-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 8 Adverse events (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 9 Serious adverse events at 12 months." data-id="CD010233-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 9 Serious adverse events at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 10 Withdrawal due to adverse events at 12 to 24 months." data-id="CD010233-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 10 Withdrawal due to adverse events at 12 to 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 11 Withdrawal due to adverse events (subgroup by length of follow‐up)." data-id="CD010233-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 11 Withdrawal due to adverse events (subgroup by length of follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010233-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/urn:x-wiley:14651858:media:CD010233:CD010233-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_t/tCD010233-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 12 HRQoL ‐ IBDQ &gt; 170 at 24 months." data-id="CD010233-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Azathioprine or 6‐mercaptopurine versus anti TNF‐α, Outcome 12 HRQoL ‐ IBDQ &gt; 170 at 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/media/CDSR/CD010233/image_n/nCD010233-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010233-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine (100‐150 mg/day) or 6‐mercaptopurine (1 mg/kg/day ‐ 50 mg/day)<br/> <b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79<br/> (0.67 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>408<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse defined as: a CDAI&gt;250 (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>); a CDAI&gt;150 and 100 point increase from baseline (<a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>) or a grading score &gt; 2 (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>). </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>642 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1,000<br/> (430 to 591) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Endoscopic relapse</b> </p> <p>Follow‐up:12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/> (0.64 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>321<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic relapse defined as an endoscopic score i ≥2 (<a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a>; <a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>752 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>639 per 1,000<br/> (481 to 849) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiologic relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Surgical relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.36<br/> (0.57 to 3.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>168<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported adverse events include hair loss, leukopenia, diarrhoea, abdominal pain, hepatotoxicity and arthralgia </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>99 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000<br/> (56 to 323) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up:12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.78<br/> (0.39 to 8.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>327<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported serious adverse events include arthralgia, pancreatitis, leucopenia and bowel obstruction </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1,000<br/> (5 to 108) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up:12 to 36 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.63 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>408<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal included abnormal blood results leading to temporary discontinuation of treatment in 28% of the participants. However, specific details on reasons for discontinuation were not clearly stated </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1,000<br/> (160 to 328) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due serious imprecision (233 events). </p> <p><sup>2</sup> Downgraded one level due to serious inconsistency ( I² = 64%). </p> <p><sup>3</sup> Downgraded one level due to serious imprecision (227 events). </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (20 events) and 95% CI which includes appreciable benefit and harm </p> <p><sup>5</sup> Downgraded two levels due to very serious imprecision (7 events) and 95% CI which includes appreciable benefit and harm </p> <p><sup>6</sup> Downgraded one level due to serious imprecision (100 events) and 95% CI which includes appreciable benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to placebo for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010233-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine compared to 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine (2 mg/kg/day) or 6‐mercaptopurine (50 mg/day)<br/> <b>Comparison:</b> 5‐aminosalicylic acid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with 5‐aminosalicylic acid</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05 (0.89, 1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>347<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse defined as a clinical grading score ≥ 2 (<a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a>;<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> <p>or CDAI ≥ 200 (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>556 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>595 per 1,000<br/> (456 to 773) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Endoscopic relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/> (0.52 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic relapse defined as a Rugeerts score ≥ 2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>650 per 1,000<br/> (433 to 975) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.66 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>35<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Radiologic relapse defined as a radiographic grading score ≥ 2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>767 per 1,000<br/> (550 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Surgical relapse</b> </p> <p>Follow‐up: 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.50 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>142<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Surgical relapse defined as a need for another surgery (<a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>366 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>297 per 1,000<br/> (183 to 472) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/> (0.74 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>346<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported adverse events include leukopenia, abdominal pain, nausea, nasopharyngitis, diarrhoea. and headache </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1,000<br/> (353 to 510) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.39<br/> (1.26 to 9.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>311<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Reported serious adverse events include postoperative bowel obstruction</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000<br/> (50 to 360) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.21 (1.28, 3.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>425<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal include Severe epigastric intolerance, increase in liver function test results, leukopenia, acute pancreatitis </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>76 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1,000<br/> (93 to 317) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of bias </p> <p><sup>2</sup> Downgraded one level due to serious imprecision (214 events) and 95% CI which includes no effect and appreciable harm </p> <p><sup>3</sup> Downgraded two levels due to very serious imprecision (26 events) and 95% CI which includes no effect and appreciable benefit </p> <p><sup>4</sup> Downgraded two levels due to very serious imprecision (28 events) and 95% CI which includes no effect and appreciable benefit </p> <p><sup>5</sup> Downgraded two levels due to very serious imprecision (47 events) and 95% CI which includes appreciable benefit and harm </p> <p><sup>6</sup> Downgraded one level due to serious imprecision (154 events) and 95% CI which includes no effect and appreciable benefit </p> <p><sup>7</sup> Downgraded two levels due to serious imprecision (33 events) </p> <p><sup>8</sup> Downgraded one level due to serious imprecision (58 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010233-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to anti TNF‐α for maintenance of surgically‐induced remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Azathioprine or 6‐mercaptopurine compared to anti‐TNF‐α for maintenance of surgically‐induced remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People with surgically‐induced remission in Crohn's disease<br/> <b>Setting:</b> Outpatient<br/> <b>Intervention:</b> Azathioprine (2‐2.5 mg/kg/day) or 6‐mercaptopurine (1.5 mg/kg/day)<br/> <b>Comparison:</b>Anti‐TNF‐α </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anti‐ TNF‐α</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Azathioprine or 6‐mercaptopurine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Clinical relapse</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.89<br/> (1.50 to 5.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>139<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> VERY LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Clinical relapse defined as: an HBI ≥2 (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>), a clinical recurrence grading score ≥2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) </p> <p>or a CDAI score &gt;200 (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1,000<br/> (208 to 774) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Endoscopic relapse</b> Follow‐up: 12 to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.67<br/> (1.05 to 12.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>157<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Endoscopic relapse defined as a Rugeerts score ≥ 2 (<a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a>; <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>; <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>; <a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>973 per 1,000<br/> (278 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Radiologic relapse</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Radiologic relapse defined as a radiographic grading score ≥ 2 (<a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>) or magnetic resonance enterography score ≥2 (<a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a>) </p> <p>*due to considerable heterogeneity (I² = 85%), data pooling was not feasible. It is uncertain whether azathioprine leads to a difference in radiologic relapse when compared to infliximab as the certainty of the evidence is very low (RR1.36, 95% CI 0.94 to 1.98; RR 12.24, 95% CI 1.8 to 83.12) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Surgical relapse</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>Outcome not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.13<br/> (0.83 to 1.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>117<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events include bronchitis, nasopharyngitis, arthralgia, nausea, abscess were reported in <a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a>. Full details were not reported in <a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>508 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>574 per 1,000<br/> (422 to 778) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.51<br/> (0.17 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>84<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events not reported</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1,000<br/> (34 to 308) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Withdrawal due to adverse events</b> </p> <p>Follow‐up: 12 to 24 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.97<br/> (0.92 to 17.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>139<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events leading to withdrawal included severe nausea, leukopenia, arthralgia, urothelial carcinoma, dyspepsia, dyspnoea, death, atopic dermatitis and abdominal pain with increase in pancreatic enzymes </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1,000<br/> (26 to 478) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of bias </p> <p><sup>2</sup> Downgraded two levels due to very serious imprecision (39 events) </p> <p><sup>3</sup> Downgraded one level due to serious imprecision (65 events) </p> <p><sup>4</sup> Downgraded one level due to substantial heterogeneity (I² = 64%) </p> <p><sup>5</sup> Downgraded one level due to serious imprecision (63 events) </p> <p><sup>6</sup> Downgraded two levels due to very serious imprecision (13 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine compared to anti TNF‐α for maintenance of surgically‐induced remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010233-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Key definitions and outcomes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time from surgery till recruitment</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Site of surgery % / exclusions</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical relapse definition</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic / surgical/ radiologic/ histological relapse definition/</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>AZA &amp; 6‐MP versus Placebo </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA versus Placebo (12 months)</p> <p>both arms 750 mg/day metronidazole</p> <p>(3 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perforating disease 48</p> <p>*Macroscopic evidence for CD proximally or distally to the site of resection or the presence of frank pancolitis or an ileorectal anastomosis, patients with a stoma; operation for fibrostenosis only </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 250</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 50 mg/day versus Placebo</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before postoperative hospital discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical recurrence grading &gt; 2 (Hanauer)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiographic relapse: </b> Radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 1 mg/kg/day versus Placebo</p> <p>(3 years)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 39; Colonic 2; Ileocolonic 59</p> <p>* Need for further surgery, stricturoplasty alone, formation of a stoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 150 and a 100‐point increase from baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>HRQOL:</b> IBDQ scores </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>AZA &amp; 6‐MP vs 5‐ASA </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg versus Mesalamine 3 mg/kg (24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximum 2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small bowel only 25.3; Colon 5.6; Small bowel and colon 9.8; upper gastrointestinal tract 16.2 </p> <p>*Surgical procedures other than conservative surgery or for perianal disease only</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 200</p> <p><b>Surgical relapse: </b> need for another surgical procedure </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 50 mg/day versus Mesalamine 3 g/day</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Before postoperative hospital discharge</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p>* Active perianal disease or any active disease in other segments of the intestine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinical recurrence grading &gt; 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiographic relapse: </b> radiographic recurrence grading &gt; 2 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg/day versus Mesalamine 4 g/day</p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐24 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> <p>* Short bowel syndrome, an ileocolonic stoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>HRQOL: IBDQ </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg/day versus Mesalazine 3 g/day</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51.</p> <p>* Fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 on the clinical recurrence grading scale by Hanauer</p> <p>2. CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i≥2</p> <p><b>Radiologic relapse </b>: ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQl: </b> IBDQ&gt;170 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>AZA &amp; 6‐MP vs anti‐TNF‐α </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2.5 mg versus Infliximab 5 mg/kg</p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>*Active perianal disease, presence of stoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HBI ≥ 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts' score ≥ i2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2 mg/kg/day versus Adalimumab</p> <p>(24 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileum 49, Ileocolonic 51.</p> <p>* Fibrostenotic stricture, macroscopically active disease not resected at the time of surgery, and presence of a stoma </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. ≥ 2 on the clinical recurrence grading scale by Hanauer</p> <p>2. CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> <p><b>Radiologic relapse </b>: ≥ 2 radiographic recurrence grading scale </p> <p><b>HRQl: </b> IBDQ &gt; 170 </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AZA 2.5 mg/kg/day versus Adalimumab</p> <p>(52 weeks)</p> <p>both arms 750mg/day metronidazole</p> <p>(3 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ileal 58, ileocolonic 41</p> <p>* Postsurgical stoma, resection for short indolent stenosis, inaccessible anastomosis to endoscopy </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDAI &gt; 200</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rutgeerts i ≥ 2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 1.5 mg/kg/day versus Adalimumab</p> <p>(12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 45 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐MP 1.5 mg/kg/day vs Placebo (12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scapa 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 45 days</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>AZA: azathioprine; 6‐MP: 6‐mecarptopurine; mg: milligram; CD: Crohn's disease; CDAI: Crohn's disease activity index; NA: not applicable; kg: kilogram; g: gram; HRQOL: health related quality of life; IBDQ: inflammatory bowel disease questionnaire; TNF: tumour necrosis factor; HBI: Harvey Bradshaw index; 5‐ASA: 5‐aminosalicylic acid </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Key definitions and outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010233-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of interventions and outcomes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 1</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 2</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Group 3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quailty</b> </p> <p><b>of Life</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse</b> </p> <p><b>Events/</b> </p> <p><b>Serious</b> </p> <p><b>adverse/ Withdrawal due to adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0001" title="ArdizzoneS , MaconiG , SampietroGM , RussoA , RadiceE , ColomboE , et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology2004;127(3):730‐40. ">Ardizzone 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine</p> <p>(3g/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 32/71 vs 35/71 </p> <p><b>Surgical:</b> 26/71 vs 21/71 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b>18/71 vs 27/71 </p> <p><b>SAE</b>:6/71 vs 15/71 </p> <p><b>Withdrwal due to AE:</b> 6/71 vs 15/71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0002" title="ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Infliximab is more effective than azathioprine in the long‐term prevention of postoperative recurrence of Crohn's disease. GastroenterologyApril 2015;1:S856. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: A pilot study. Digestive and Liver Disease2012;44:S194. ArmuzziA , FeliceC , MarzoM , PuglieseD , AndrisaniG , PapaA , et al. Prevention of postoperative recurrence with azathioprine or anti‐TNF alpha in patients with Crohn's disease: An open‐label pilot study. Gastroenterology2012;142(5 Suppl 1):S780. ArmuzziA , FeliceC , PapaA , MarzoM , PuglieseD , AndrisaniG , et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open‐label pilot study. Journal of Crohn's and Colitis2013;7(12):e623‐9. ">Armuzzi 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine</p> <p>(2.5 mg/kg/day)</p> <p>Infliximab</p> <p>(5 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infliximab</p> <p>(5 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 2/11 vs 1/11 </p> <p><b>Endoscopic:</b> 5/11 vs 1/11; </p> <p><b>Histologic:</b> 9/11 vs 2/11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal due to AE:</b> 0/11 vs 1/11 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0003" title="D'HaensG , VermeireS , VanAsscheG , NomanM , AerdenI , VanOlmenG , et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroeneterology2008;135(4):1123‐9. D'HaensGR , NomanM , VanAsscheGA , VanOlmenG , AerdenI , VermeireS , et al. Combination therapy with metronidazole and azathioprine reduces severe postoperative recurrence of Crohn's disease: A double‐blind controlled randomized trial. Gastroenterology 20072007;132(4 Suppl 1):A52. ">D'Haens 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole (750 mg/day) first 3 mo +</p> <p>Azathioprine (100‐150 mg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metronidazole (750mg/day) first 3 months +</p> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 11/40 vs 19/41 </p> <p><b>Endoscopic:</b> 22/40 vs 32/41 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 3/40 vs 4/41 </p> <p><b>Withdrawal due to AE:</b> 3/40 vs 4/41 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0004" title="HanauerSB , KorelitzBI , RutgeertsP , PeppercornMA , ThistedRA , CohenRD , et al. Postoperative maintenance of Crohn's disease remission with 6‐mercaptopurine, mesalamine or placebo: a 2‐year trial. Gastroenterology2004;127(3):723‐9. KorelitzB , HanauerS , RutgeertsP , PresentD , PeppercornM . Post‐operative prophylaxis with 6‐MP, 5‐ASA or placebo inCrohn's disease: A 2 year multicenter trial. Gastroenterology1998;114(4 Part 2):A486. ">Hanauer 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐Mercaptopurine (50 mg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical:</b> 32/47 vs 33/44 vs 35/40 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 9/47 vs 6/44 vs 4/40 </p> <p><b>SAE:</b> 2/47 vs 0/44 vs 2/40 </p> <p><b>Withdrawal due to AE:</b> 9/47 vs 6/44 vs 4/40 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0006" title="Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Adalimumab vs azathioprine in the prevention of postoperative Crohn’s disease recurrence. A GETECCU randomised trial. Journal of Crohn's and Colitis2017;11(11):1293–301. Lopez‐SanromanA , Vera‐MendozaI , DomenechE , TaxoneraC , VegaV , Marin‐JimenezI , et al. Apprecia: Adalimumab vs azathioprine in the prevention of Crohn's disease recurrence after surgical resection. A geteccu multicenter randomized trial. United European Gastroenterology Journal2015;1:A3. NCT01564823 . Adalimumab on Preventing Post‐chirurgic Recurrence on Crohn's Disease (APPRECIA). clinicaltrials.gov/ct2/show/NCT01564823 (accessed 28 March 2012). TaxoneraC , López‐SanrománA , Vera‐MendozaI , DomènechE , RuizVV , Marín‐JiménezI , et al. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. Digestive and Liver Disease2019;51(4):529‐35. ">Lopez‐Sanroman 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2.5 mg/kg/d) + Metronidazole (750 mg/day) first 3 mo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab + Metronidazole (750 mg/day) first 3 mo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical:</b> 14/39 vs 7/45 </p> <p><b>Endoscopic:</b> 23/39 vs 19/45 </p> <p><b>Radiologic:</b> 26/39 vs 22/45 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n.s. changes between groups</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 20/45 vs 18/39 </p> <p><b>SAE:</b> 9/45 vs 4/39 </p> <p><b>Withdrawal due to AE:</b> 1/39 vs 9/45 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0007" title="ArnottI , MowatC , EnnisH , KeerieC , LewisS , CahillA , et al. The toppic trial: A randomised, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gut2016;65(Suppl 1):A43‐4. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The TOPPIC trial: A randomised, double‐blind parallel‐group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Journal of Crohn's and Colitis2016;10(1 Supplement):S21‐S22. ArnottI , MowatC , EnnisH , KeerieC , LewisS , KennedyN , et al. The toppic trial: A randomized, double‐blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients. Gastroenterology2016;150(4 Suppl 1):S182. ISRCTN89489788 . Randomised controlled trial of 6‐Mercaptopurine (6MP) versus placebo to prevent recurrence of Crohn's disease following surgical resection. isrctn.com/ISRCTN89489788 (accessed 22 February 2007). MowatC , ArnottI , CahillA , SmithM , AhmadT , SubramanianS , et al. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): A multicentre, double‐blind, randomised controlled trial. Lancet2016;1(4):273‐82. ">Mowat 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mercaptopurine (1 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical:</b> 66/128 vs 70/112 </p> <p><b>Endoscopic:</b> 90/128 vs 83/112 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n.s differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SAE:</b> 3/128 vs 2/112 </p> <p><b>Withdrawal due to AE:</b> 39/128 vs 41/112 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0008" title="AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflammatory Bowel Diseases2013;19:590‐8. AngelbergerS , SchaeffelerE , TemlA , PetritschW , ShonovaO , LukasM , et al. Relationship between thiopurine metabolite levels and endoscopic improvement in patients with postoperative moderate to severe endoscopic recurrence of Crohn'sdisease. Gastroenterology2010;138(5 Suppl 1):S685. NCT00946946 . Preventing postoperative relapse in Crohn's disease patients at risk: Azathioprine versus mesalazine. clinicaltrials.gov/ct2/show/NCT00946946 (accessed 27 July 2009). ReinischW , AngelbergerS , PetritschW , HerrlingerK , ShonovaO , LukasM , et al. A double‐blind, double‐dummy,randomized, controlled, multicenter trial on the efficacy and safety of azathioprine vs mesalamine for prevention of clinical relapses in Crohn's disease patients with postoperative moderate or severe endoscopic recurrence. Gastroenterology2008;134(4 Suppl 1):A70. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , Bar‐MeirS , et al. Azathioprine versus mesalazine for the prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomized, double‐blind, double‐dummy, multicentre trial. Gut2010;59(6):752‐9. ReinischW , AngelbergerS , PetritschW , ShonovaO , LukasM , GreinwaldR , et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in Crohn's disease patients with endoscopic recurrence: Follow‐up data of a randomised, double‐blind, double‐dummy, 1‐year, multicentre trial. Journal of Crohn's and Colitis2013;7:S254. ReinischW , StangeEF . Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease ‐ the authors' response. Gut2011;60(5):739‐40. ">Reinisch 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2.0‐2.5 mg/kg/d) + Placebo mesalazine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalazine (4g/d) +</p> <p>Placebo azathioprine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not included</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean IBDQ change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>AE:</b> 34/37 vs 32/41 </p> <p><b>SAE:</b> 0/37 vs 10/41 </p> <p><b>Withdrawal due to AE:</b> 1/37 vs 10/41 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0009" title="BodiniG , PellegattaG , GianniniEG , SavarinoV , SavarinoEV . Adalimumab therapy rather than azathioprine and mesalamine is able to halt Crohn's disease progression after resective surgery and a post‐hoc analysis of a prospective randomized study. Gastroenterology. 2017; Vol. 152, issue 5 Supplement:S774. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Digestive and Liver Disease2013;45:S94‐5. SavarinoE , BodiniG , DulbeccoP , AssandriL , BruzzoneL , MazzaF , et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. American Journal of Gastroenterology2013;108(11):1731‐42. SavarinoE , BodiniG , DulbeccoP , MarabottoE , AssandriL , BruzzoneL . Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease ‐ a randomized trial. Gastroenterology2013;144(5 Suppl 1):S21. ">Savarino 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab (160‐80 mg 0‐2 weeks and 40 mg/week thereafter)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azathioprine (2 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesalamine (3 g/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical by Hanauer score:</b> 2/16 vs 12/17 vs 9/18 </p> <p><b>Clinical by CDAI:</b> 1/16 vs 12/17 vs 9/18 </p> <p><b>Endoscopic:</b> 1/16 vs 11/17 vs 15/18 </p> <p><b>Radiologic:</b> 1/16 vs 13/17 vs 15/18 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HRQOL (IBDQ &gt;170):</p> <p>14/16 vs 2/17 vs 3/18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE:</b>11/16 vs 14/17 vs 14/18 </p> <p><b>Withdrawal due to AE:</b>0/16 vs 1/17 vs 1/18 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010233-bbs2-0010" title="NCT01629628 . Adalimumab for the Management of Post‐operative Crohn's Disease (CD) POPART. clinicaltrials.gov/ct2/show/NCT01629628 (accessed 27 June 2012). ScapaE , MaharshakN , KarivY , Ben‐HorinS , WhiteID , SantoE , et al. Early initiation of adalimumab significantly diminishes post‐operative Crohn's disease recurrence, and is superior to immunomodulator therapy. Preliminary results from the POPART trial. Gastroenterology2015;148(4 Supplement):S240‐1. ">Scapa 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐mercaptopurine (1.5 mg/kg/day)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adalimumab (160‐80‐40 mg/2 week intervals)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Endoscopic:</b> 4/8 vs 1/11 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>mg: milligram; kg: kilogram; g: gram; CDAI: Crohn's disease activity index; NA: not applicable; AE: adverse events; SAE: serious adverse events; HRQOL: health related quality of life; IBDQ: inflammatory bowel disease questionnaire; ns: not significant </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of interventions and outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/full#CD010233-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010233-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 12 to 36 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.67, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.33, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.68, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical relapse (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.67, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.33, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.68, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Endoscopic relapse at 12 to 36 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.64, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.51, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.81, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Endoscopic relapse (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.64, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.51, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.81, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events at 12 to 24 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.57, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.18, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.64, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.57, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.18, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.64, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events at 24 to 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.39, 8.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawal due to adverse events at 12 to 36 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.63, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.18, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.50, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawal due to adverse events (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.63, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.18, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.50, 2.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010233-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 12 to 24 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.94, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical relapse (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.84, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.82, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Endoscopic relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Radiologic relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Surgical relapse at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events at 12 to 24 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.54, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.64, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse events at 12 to 24 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [1.26, 9.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [0.64, 34.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [0.23, 95.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [1.26, 9.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.00 [1.15, 313.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [1.12, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawal due to adverse events at 12 to 24 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.28, 3.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [1.41, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.54, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Withdrawal due to adverse events (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.28, 3.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.54 [0.83, 15.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.03, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 HRQoL ‐ IBDQ &gt; 170 at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 HRQoL ‐ IBDQ at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus 5‐aminosalicylic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010233-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus anti TNF‐α</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical relapse at 12 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [1.50, 5.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical relapse (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [1.50, 5.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [1.07, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.12 [1.63, 22.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Endoscopic relapse at 12 to 24 months (subgroup by drug type) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.67 [1.05, 12.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Azathioprine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [0.75, 16.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 6‐mercaptopurine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.5 [0.75, 40.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Endoscopic relapse (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.67 [1.05, 12.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [0.83, 7.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.35 [1.50, 71.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Radiologic relapse at 12 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Histologic relapse at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events at 12 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.83, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.83, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.65, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.81, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Serious adverse events at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawal due to adverse events at 12 to 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.97 [0.92, 17.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Withdrawal due to adverse events (subgroup by length of follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.17 [0.99, 17.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 12 months or less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.17 [1.32, 38.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.07, 15.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 HRQoL ‐ IBDQ &gt; 170 at 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Azathioprine or 6‐mercaptopurine versus anti TNF‐α</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010233.pub3/references#CD010233-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010233.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010233-note-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010233-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010233-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010233-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010233-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD010233-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010233-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010233\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010233\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010233\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010233\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010233\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010233.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010233.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010233.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010233.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010233.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716975656"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010233.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716975660"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010233.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daca19b70f3f1',t:'MTc0MDcxNjk3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 